<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Environ Res Public Health</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Environ Res Public Health</journal-id>
<journal-id journal-id-type="publisher-id">ijerph</journal-id>
<journal-title-group>
<journal-title>International Journal of Environmental Research and Public Health</journal-title>
</journal-title-group>
<issn pub-type="ppub">1661-7827</issn>
<issn pub-type="epub">1660-4601</issn>
<publisher>
<publisher-name>MDPI</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27834829</article-id>
<article-id pub-id-type="pmc">5129306</article-id>
<article-id pub-id-type="doi">10.3390/ijerph13111096</article-id>
<article-id pub-id-type="publisher-id">ijerph-13-01096</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>MiRNAs and miRNA Polymorphisms Modify Drug Response</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Mu-Peng</given-names>
</name>
<xref ref-type="aff" rid="af1-ijerph-13-01096">1</xref>
<xref ref-type="aff" rid="af2-ijerph-13-01096">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Yao-Dong</given-names>
</name>
<xref ref-type="aff" rid="af3-ijerph-13-01096">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Xiao-Lei</given-names>
</name>
<xref ref-type="aff" rid="af1-ijerph-13-01096">1</xref>
<xref ref-type="aff" rid="af2-ijerph-13-01096">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Yan-Jiao</given-names>
</name>
<xref ref-type="aff" rid="af1-ijerph-13-01096">1</xref>
<xref ref-type="aff" rid="af2-ijerph-13-01096">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Yong-Long</given-names>
</name>
<xref ref-type="aff" rid="af4-ijerph-13-01096">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Chun</given-names>
</name>
<xref ref-type="aff" rid="af1-ijerph-13-01096">1</xref>
<xref ref-type="aff" rid="af2-ijerph-13-01096">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tang</surname>
<given-names>Jie</given-names>
</name>
<xref ref-type="aff" rid="af1-ijerph-13-01096">1</xref>
<xref ref-type="aff" rid="af2-ijerph-13-01096">2</xref>
<xref ref-type="corresp" rid="c1-ijerph-13-01096">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Xiao-Ping</given-names>
</name>
<xref ref-type="aff" rid="af1-ijerph-13-01096">1</xref>
<xref ref-type="aff" rid="af2-ijerph-13-01096">2</xref>
<xref ref-type="corresp" rid="c1-ijerph-13-01096">*</xref>
</contrib>
</contrib-group>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>Cho</surname>
<given-names>William Chi-shing</given-names>
</name>
<role>Academic Editor</role>
</contrib>
</contrib-group>
<aff id="af1-ijerph-13-01096"><label>1</label>Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; <email>elskesunny@163.com</email> (M.-P.L.); <email>huxiaolei66@126.com</email> (X.-L.H.); <email>zhangyj287112687@163.com</email> (Y.-J.Z.); <email>JChun213@163.com</email> (C.J.)</aff>
<aff id="af2-ijerph-13-01096"><label>2</label>Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China</aff>
<aff id="af3-ijerph-13-01096"><label>3</label>Department of Cardiology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi 046000, China; <email>leexz2010@163.com</email></aff>
<aff id="af4-ijerph-13-01096"><label>4</label>Haikou People’s Hospital and Affiliated Haikou Hospital of Xiangya Medical School, Central South University, Haikou 570311, China; <email>yyl0756@yeah.net</email></aff>
<author-notes>
<corresp id="c1-ijerph-13-01096"><label>*</label>Correspondences: <email>chenxp74@hotmail.com</email> (X.-P.C.); <email>jietang@csu.edu.cn</email> (J.T.); Tel.: +86-731-8480-5380 (X.-P.C. &amp; J.T.); Fax: +86-731-8235-4476 (X.-P.C. &amp; J.T.)</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>11</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>11</month>
<year>2016</year>
</pub-date>
<volume>13</volume>
<issue>11</issue>
<elocation-id>1096</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>9</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>10</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© 2016 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
<copyright-year>2016</copyright-year>
<license>
<license-p><!--CREATIVE COMMONS-->This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Differences in expression of drug response-related genes contribute to inter-individual variation in drugs’ biological effects. MicroRNAs (miRNAs) are small noncoding RNAs emerging as new players in epigenetic regulation of gene expression at post-transcriptional level. MiRNAs regulate the expression of genes involved in drug metabolism, drug transportation, drug targets and downstream signal molecules directly or indirectly. MiRNA polymorphisms, the genetic variations affecting miRNA expression and/or miRNA-mRNA interaction, provide a new insight into the understanding of inter-individual difference in drug response. Here, we provide an overview of the recent progress in miRNAs mediated regulation of biotransformation enzymes, drug transporters, and nuclear receptors. We also describe the implications of miRNA polymorphisms in cancer chemotherapy response.</p>
</abstract>
<kwd-group>
<kwd>microRNA</kwd>
<kwd>drug response</kwd>
<kwd>miRNA polymorphisms</kwd>
<kwd>prognosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-ijerph-13-01096">
<title>1. Introduction</title>
<p>Drug responses are complex traits determined by both genetic and environmental factors. Variations in expression of drug response-related proteins such as drug-metabolizing enzymes (DMEs), drug transporters and therapeutic mechanisms (including drug targets and downstream signal molecules) are the important source of inter-individual variability in drug response. In spite of genetic factors, epigenetic modification of gene expression at transcriptional and post-transcriptional levels contributes to variations in the expression of drug response related genes [<xref ref-type="bibr" rid="B1-ijerph-13-01096">1</xref>]. Accumulated evidence has shown that genes encoding DMEs, drug transporters, nuclear receptors, and drug targets are under epigenetic control [<xref ref-type="bibr" rid="B1-ijerph-13-01096">1</xref>,<xref ref-type="bibr" rid="B2-ijerph-13-01096">2</xref>]. Pharmacoepigenomics, a newly emerged field of combined study on genetic variations and epigenetic modifications in drug response, is supposed to expand the scope of pharmacogenomics and may provide more definite answers to the role of environmental factors in variable drug response [<xref ref-type="bibr" rid="B3-ijerph-13-01096">3</xref>].</p>
<p>In addition to transcriptional regulation of gene expression by DNA methylation, histone modification and xenosensor modulation, microRNAs (miRNAs) mediated post-transcriptional regulation is a newly recognized mechanism of gene expression regulation that attracts much interest in recent years [<xref ref-type="bibr" rid="B4-ijerph-13-01096">4</xref>]. Understanding of the miRNA-related mechanisms in drug response opens a new field in pharmacogenetics and pharmacoepigenomics. In this review, we focused on miRNA and its prospects in pharmacogenomics and translational medicine. PubMed, EMBASE, and Web of Science databases were searched up to July 2016 for studies that evaluated associations between miRNAs as well as miRNA polymorphisms and drug response. Relevant publications were identified by searching for combinations of “miRNAs”, “drug metabolizing enzymes”, “drug transporters”, “miRNA polymorphisms”, “drug response” and their synonyms.</p>
</sec>
<sec id="sec2-ijerph-13-01096">
<title>2. MiRNAs: A New Player in Gene Function and Drug Response</title>
<p>MiRNAs bind to complementary regions of the target transcripts and regulate gene expression via translational repression or mRNA degradation (<xref ref-type="fig" rid="ijerph-13-01096-f001">Figure 1</xref>). Up to date, about 1881 miRNAs are identified in human genome [<xref ref-type="bibr" rid="B5-ijerph-13-01096">5</xref>]. However, only 523 human miRBase entries are robustly supported as miRNA genes [<xref ref-type="bibr" rid="B5-ijerph-13-01096">5</xref>]. Given miRNAs function as important regulators of a wide range of cellular processes, identification of canonical miRNA becomes particularly important. It is estimated that more than 60% of human protein-coding genes harbor miRNA target sites in their 3’-untranslated regions (3’-UTRs), and miRNAs are predicted to control about 30% of human genes [<xref ref-type="bibr" rid="B6-ijerph-13-01096">6</xref>]. Roles of miRNAs in organ development and pathogenesis of human diseases have been extensively studied in recent years [<xref ref-type="bibr" rid="B7-ijerph-13-01096">7</xref>]. The expression of some DMEs, drug transporters, and drug targets can also be regulated by miRNAs through direct or indirect mechanisms [<xref ref-type="bibr" rid="B8-ijerph-13-01096">8</xref>]. MiRNA-mediated gene regulation provides new insight into the understanding of variations in an individual’s response to therapeutic drugs.</p>
</sec>
<sec id="sec3-ijerph-13-01096">
<title>3. MiRNAs-Mediated Regulation of DMEs and Drug Transporters</title>
<p>Numerous studies have demonstrated that miRNAs can regulate DMEs and drug transporters, including cytochrome P450s (CYP450s), ABC and SLC transporters, and xenobiotic receptors (<xref ref-type="table" rid="ijerph-13-01096-t001">Table 1</xref>).</p>
<sec id="sec3dot1-ijerph-13-01096">
<title>3.1. Direct Repression of DME by miRNAs</title>
<p>CYP450s superfamily, the largest group of phase I enzymes, catalyze a huge diversity of drugs in adult human liver. MiRNA-mediated epigenetic regulation is observed to affect CYP450 expression [<xref ref-type="bibr" rid="B8-ijerph-13-01096">8</xref>].</p>
<p>CYP1A1 is responsible for the metabolisms of carcinogenic metabolites, such as benzo(a)pyrene. A positive correlation between miR-18b as well as miR-20b and CYP1A1 mRNA levels was observed in immortalized lymphoblastiod cell lines [<xref ref-type="bibr" rid="B9-ijerph-13-01096">9</xref>]. However, miR-18b and miR-20b exhibited no correlation with CYP1A1 mRNA and protein levels in human liver tissue [<xref ref-type="bibr" rid="B10-ijerph-13-01096">10</xref>]. Moreover, luciferase assays revealed that CYP1A1 is a direct target of miR-892a [<xref ref-type="bibr" rid="B11-ijerph-13-01096">11</xref>]. A significant negative correlation was observed between miR‑892a level and CYP1A1 protein expression [<xref ref-type="bibr" rid="B11-ijerph-13-01096">11</xref>]. Recently, mRNA and protein levels of CYP1A1 exhibited negative correlation with miR-132, miR-142-3p, and miR-21 in a cohort of 92 human liver tissue [<xref ref-type="bibr" rid="B10-ijerph-13-01096">10</xref>].</p>
<p>CYP2A13 is critical for the metabolic activation of the tobacco-specific carcinogen 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK), a potent and tobacco-specific procarcinogen [<xref ref-type="bibr" rid="B12-ijerph-13-01096">12</xref>]. CYP2A3 is the orthologue of human CYP2A13 in rats. In a study mimicking the early stages of lung cancer development in rats under chronic NNK exposure, Kalscheuer et al., observed that the expression of several miRNAs, such as miR-101, miR-126*, miR-199 and miR-34, was decreased, while the expression of CYP2A3 was increased in the early stage of tumorigenesis, and reporter assays showed <italic>CYP2A3</italic> is a direct target of miR-126* [<xref ref-type="bibr" rid="B13-ijerph-13-01096">13</xref>].</p>
<p>CYP1B1 is involved in metabolism of several procarcinogens and chemotherapeutic drugs such as doxorubicin. It was the first reported CYP450 isoenzyme undergoing miRNA regulation. The expression levels of miR-27b [<xref ref-type="bibr" rid="B14-ijerph-13-01096">14</xref>] and miR-200c [<xref ref-type="bibr" rid="B15-ijerph-13-01096">15</xref>] correlated reversely with CYP1B1 protein in breast cancerous and renal cell cancer tissues, respectively. As miR-27b exhibits lower levels in breast cancer, the miR-27b mediated translational inhibition of CYP1B1 expression may account for the tumor-specific expression of CYP1B1 at protein level rather than mRNA level in breast cancer [<xref ref-type="bibr" rid="B16-ijerph-13-01096">16</xref>]. Upregulation of CYP1B1 due to miR-27b and miR-200c downregulation may thus lead to decreased drug response in cancer.</p>
<p>CYP2C8 is involved in the detoxification of more than 60 clinical drugs. Transfection of miR-103 or miR-107 precursors decreases CYP2C8 protein level via MRE within the <italic>CYP2C8</italic> 3’-UTR in primary human hepatocytes [<xref ref-type="bibr" rid="B17-ijerph-13-01096">17</xref>]. Furthermore, inhibition of these miRNAs results in an increase in CYP2C8 protein expression [<xref ref-type="bibr" rid="B17-ijerph-13-01096">17</xref>]. In addition, miR-21, miR-27a, miR-142-3p, miR-223, and miR-539 exhibited reverse correlation with CYP2C8 mRNA level in human liver tissue [<xref ref-type="bibr" rid="B10-ijerph-13-01096">10</xref>].</p>
<p>CYP2C9 is responsible for metabolism of about 20% of clinically used drugs, such as warfarin and phenytoin. In a human liver tissue, CYP2C9 mRNA level exhibited negative correlation with numerous miRNAs, of which the most significant miRNAs were miR-16, miR-17, miR-29a, and miR-28-3p [<xref ref-type="bibr" rid="B10-ijerph-13-01096">10</xref>]. Furthermore, overexpression of miR-128-3p could suppress CYP2C9 mRNA and protein expression in HepaRG cells [<xref ref-type="bibr" rid="B18-ijerph-13-01096">18</xref>]. MiR-128-3p expression was inversely correlated with <italic>CYP2C9</italic> mRNA expression in hepatocellular carcinoma (HCC) tumor tissues [<xref ref-type="bibr" rid="B18-ijerph-13-01096">18</xref>]. And luciferase reporter assay revealed that <italic>CYP2C9</italic> was targeted directly by miR-128-3p [<xref ref-type="bibr" rid="B18-ijerph-13-01096">18</xref>].</p>
<p>CYP2C19 is a monooxygenase which metabolizes many clinically prescribed therapeutic agents, including selective serotonin reuptake inhibitors, proton pump inhibitors, clopidogrel, citalopram, diazepam, and imipramine. Overexpression of miR-103 and miR-107 could reduce CYP2C19 protein level in human primary hepatocytes [<xref ref-type="bibr" rid="B17-ijerph-13-01096">17</xref>]. Also, miR-34a, miR-130b, miR-185 displayed a negative correlation with <italic>CYP2C9</italic> mRNA level in human liver tissue [<xref ref-type="bibr" rid="B10-ijerph-13-01096">10</xref>]. Recently, in silico analysis indicated <italic>CYP2C19</italic> can be targeted by miR-29a-3p [<xref ref-type="bibr" rid="B19-ijerph-13-01096">19</xref>]. In addition, an inverse correlation was found between miR-29a-3p and CYP2C19 mRNA or protein expression in HepaRG cells and human liver tissue samples [<xref ref-type="bibr" rid="B19-ijerph-13-01096">19</xref>]. CYP2E1 catalyzes the oxidation of many solvents and other small organic molecules. A potential miR-378 binding site was identified in the 3’-UTR of <italic>CYP2E1</italic> mRNA. In HEK293 cell lines, miR-378 overexpression can decrease CYP2E1 protein expression and chlorzoxazone 6-hydroxylation activity [<xref ref-type="bibr" rid="B20-ijerph-13-01096">20</xref>]. In addition, miR-378 expression correlates inversely with protein level and translational efficiency of CYP2E1 in human liver [<xref ref-type="bibr" rid="B20-ijerph-13-01096">20</xref>]. A recent luciferase assay suggested that miR-132 and miR-212 can directly target <italic>CYP2E1</italic> 3’-UTR, which may play a role in insulin-induced inhibition of CYP2E1 expression in primary cultured rat hepatocytes [<xref ref-type="bibr" rid="B21-ijerph-13-01096">21</xref>]. These findings helped to understand post-transcriptional regulation of <italic>CYP2E1</italic>. Also, the negative correlation between miR-10a, let-7g, and miR-200c and <italic>CYP2E1</italic> mRNA level was reported [<xref ref-type="bibr" rid="B10-ijerph-13-01096">10</xref>].</p>
<p>CYP2J2 has been found to catalyze epoxidation and hydroxylation of polyunsaturated fatty acids. More recently, let-7b was shown to repress the expression of epoxygenase CYP2J2 directly, and let-7b downregulation is associated with increased CYP2J2 expression in lung cancer [<xref ref-type="bibr" rid="B22-ijerph-13-01096">22</xref>].</p>
<p>CYP3A4 metabolizes more than 50% of therapeutic drugs. The variability of CYP3A4 expression may contribute to inter-individual difference in drug response. MiR-27b was identified to inhibit CYP3A4 mRNA/protein expression and miR-27b overexpression in PANC1 cells decreases the sensitivity to cyclophosphamide [<xref ref-type="bibr" rid="B23-ijerph-13-01096">23</xref>]. In addition, miR-577, miR-1, miR-532-3p, and miR-627 were observed to repress CYP3A4 protein expression in cultured HEK293T cells, and downregulated the translation efficiency of <italic>CYP3A4</italic> mRNA in human livers [<xref ref-type="bibr" rid="B24-ijerph-13-01096">24</xref>]. Negative correlations between levels of miRNAs including miR-155, miR-454, miR-582-5p, let-7f-1*, miR-181d, and miR-500 and hepatic CYP3A activity were observed in cirrhotic livers [<xref ref-type="bibr" rid="B25-ijerph-13-01096">25</xref>]. A recent study demonstrated that miR-27a could negatively regulate CYP3A4 mRNA and protein level in 26 human liver samples [<xref ref-type="bibr" rid="B26-ijerph-13-01096">26</xref>]. These results may reveal a difference in post-transcriptional regulation of CYPs by miRNA in cancer cells and normal tissues, but also in in vitro versus in vivo.</p>
<p>CYP7A1 is important for the regulation of bile acid synthesis in the liver. Overexpression of miR-122a and miR-422a inhibited, whereas their inhibitors promoted <italic>CYP7A1</italic> mRNA expression in human hepatocytes [<xref ref-type="bibr" rid="B27-ijerph-13-01096">27</xref>]. And luciferase reporter assay identified the binding sites of miR-122a and miR-422a in the <italic>CYP7A1</italic> 3’UTR.</p>
<p>CYP24A1 is a key enzyme in the inactivation of calcitriol, which exerts antiproliferative effects in cancer cells by binding to the vitamin D receptor. It has been reported that CYP24A1 may be a candidate oncogene and a potential prognostic biomarker for cancer [<xref ref-type="bibr" rid="B28-ijerph-13-01096">28</xref>]. A potential miR-125b recognition element was identified in the 3’-UTR of <italic>CYP24A1</italic> and <italic>VDR</italic> [<xref ref-type="bibr" rid="B29-ijerph-13-01096">29</xref>,<xref ref-type="bibr" rid="B30-ijerph-13-01096">30</xref>]. CYP24A1 protein expression was increased in breast cancer tissues, which could be explained by decreased miR-125b expression [<xref ref-type="bibr" rid="B30-ijerph-13-01096">30</xref>]. As VDR can regulate transcription of <italic>CYP24A1</italic>, miR-125b is supposed to regulate CYP24A1 expression directly and indirectly.</p>
</sec>
<sec id="sec3dot2-ijerph-13-01096">
<title>3.2. Direct Repression of Drug Transporters by miRNAs</title>
<p>Drug transporters are a group of membrane proteins that are responsible for the transportation of drugs into and out of cells. Drug transporters can be divided into uptake and efflux transporters. Uptake transporters are involved in the uptake of endogenous and exogenous substances. The soluble carrier (SLC) family are major types of uptake transporters. Efflux transporters are primary active transporters, belonging to the energy-dependent ATP-binding cassette (ABC) superfamily. Overexpression of one or more ABC transporters accounts for decreased intracellular accumulation of chemotherapeutic drugs in cancer cells and thus potentiate multidrug resistance (MDR) [<xref ref-type="bibr" rid="B31-ijerph-13-01096">31</xref>]. The cellular mechanisms of MDR include decreased drug uptake, increased drug efflux, activation of detoxifying systems, activation of DNA repair mechanisms, evasion of drug-induced apoptosis, etc. Currently, the most widely studied cellular mechanisms of tumor resistance are those associated with ABC transporter-mediated drug efflux [<xref ref-type="bibr" rid="B32-ijerph-13-01096">32</xref>]. Interests in miRNA-mediated modification of the expression of drug transporters focused on cancer MDR is increasing.</p>
<p>Multidrug resistance protein 1 (MDR1/ABCB1/P-pg) is involved in efflux of numerous drugs including antibiotics, anticancer drugs, and antiviral agents. Boyerinas et al., showed that let-7g overexpression in MDR1 positive ADR-RES cells led to a reduced P-pg expression [<xref ref-type="bibr" rid="B33-ijerph-13-01096">33</xref>]. An inverse correlation was observed between let-7g level and P-pg expression in ovarian cancer patients [<xref ref-type="bibr" rid="B33-ijerph-13-01096">33</xref>]. The expression of P-gp and <italic>MDR1</italic> mRNA can be upregulated by miR-27a and miR-451, which were observed to be higher expressed in the MDR cancer cell lines as compared with their parental lines [<xref ref-type="bibr" rid="B34-ijerph-13-01096">34</xref>]. In addition, miR-27a and miR-451 antagomir can decrease the expression of P-gp and <italic>MDR1</italic> mRNA and increase vinblastine sensitivity in MDR ovarian cancer cells [<xref ref-type="bibr" rid="B34-ijerph-13-01096">34</xref>]. MiR-27a was further identified to repress P-gp and <italic>MDR1</italic> mRNA by targeting HIPK2 in cancer cell lines A2780 and A2780/Taxol [<xref ref-type="bibr" rid="B35-ijerph-13-01096">35</xref>]. Transfection of miR-451 mimics increases sensitivity to doxorubicin in doxorubicin-resistant MCF-7 cells and irinotecan in colon carcinoma cells by binding to the <italic>MDR1</italic> 3’-UTR [<xref ref-type="bibr" rid="B36-ijerph-13-01096">36</xref>]. These findings help to understand why patients with lower miR-451 level respond worse to irinotecan-based therapy [<xref ref-type="bibr" rid="B36-ijerph-13-01096">36</xref>]. Furthermore, overexpression of miR-298 and miR-223 was reported to downregulate P-gp expression, and increase doxorubicin sensitivity in doxorubicin-resistant breast cancer cells and HCC cells [<xref ref-type="bibr" rid="B37-ijerph-13-01096">37</xref>,<xref ref-type="bibr" rid="B38-ijerph-13-01096">38</xref>]. Recently, miR-508-5p was reported to suppress expression of P-gp and <italic>MDR1</italic> mRNA by directly targeting the 3’-UTR of <italic>ABCB1.</italic> MiR-508-5p overexpression can sensitize tumours to chemotherapy in vivo in gastric cancer [<xref ref-type="bibr" rid="B39-ijerph-13-01096">39</xref>]. Another study revealed that miR-145 could regulate the expression and function of P-gp in intestinal epithelial cells [<xref ref-type="bibr" rid="B40-ijerph-13-01096">40</xref>].</p>
<p>ABCB9 is a brain and spinal cord lysosome-associated transporter. It has shown that miR-31 could inhibit cisplatin-induced apoptosis via regulating ABCB9 expression in non-small cell lung cancer cells [<xref ref-type="bibr" rid="B41-ijerph-13-01096">41</xref>]. And luciferase assay confirmed that <italic>ABCB9</italic> is a direct target of miR-31 [<xref ref-type="bibr" rid="B41-ijerph-13-01096">41</xref>].</p>
<p>Multidrug resistance-associated protein 1 (MRP1/ABCC1) mediated the active efflux of glucuronide, glutathione, and sulfate conjugates [<xref ref-type="bibr" rid="B42-ijerph-13-01096">42</xref>]. Liang and colleagues found that miR-326 expression in VP-16-resistant MCF-7 cells (MCF-7/VP) was higher than that in MCF-7 cells [<xref ref-type="bibr" rid="B43-ijerph-13-01096">43</xref>]. Furthermore, miR-326 overexpression decreases ABCC1 mRNA and protein expression by direct targeting and sensitizing MCF-7/VP cells to VP-16 and doxorubicin [<xref ref-type="bibr" rid="B43-ijerph-13-01096">43</xref>]. To identify differentially expressed miRNAs in drug sensitive and resistant small cell lung cancer cell lines that might underlie MDR, Guo et al., observed that miR-134 downregulated and ABCC1 upregulated in drug resistant cells, and miR-134 was a causal factor for downregulation of ABCC1 [<xref ref-type="bibr" rid="B44-ijerph-13-01096">44</xref>]. The liver-specific miR-122 was also reported to render adriamycin and vincristine sensitivity through inhibiting ABCB1 and ABCC1 expression in HCC [<xref ref-type="bibr" rid="B45-ijerph-13-01096">45</xref>]. In human pancreatic carcinoma PANC-1 cells, ABCC1 expression is sharply reduced by miR-1291 transfection, while miR-1291 antagomir exhibited the opposite effect [<xref ref-type="bibr" rid="B46-ijerph-13-01096">46</xref>]. The miR-1291-directed downregulation of ABCC1 sensitized the PANC-1 cells to doxorubicin [<xref ref-type="bibr" rid="B46-ijerph-13-01096">46</xref>]. Recently, miR-7 modulates chemoresistance of small cell lung cancer through modulating protein expression of ABCC1 [<xref ref-type="bibr" rid="B47-ijerph-13-01096">47</xref>].</p>
<p>ABCC2 plays an important role in resistance to platinum-based chemotherapy. Haenisch and colleagues found that miR-379 impedes ABCC2 protein expression by directly targeting 3’-UTR of <italic>ABCC2</italic> in HepG2 cells [<xref ref-type="bibr" rid="B48-ijerph-13-01096">48</xref>,<xref ref-type="bibr" rid="B49-ijerph-13-01096">49</xref>]. MiR-297 was proved to reduce ABCC2 protein expression in MDR colorectal carcinoma cells and sensitize these cells to anticancer drugs including oxaliplatin, vincristine, doxorubicin, 5-fluorouracil and mitomycin C [<xref ref-type="bibr" rid="B50-ijerph-13-01096">50</xref>]. A recent study demonstrated that let-7c sensitizes acquired cisplatin-resistant A549 cells by targeting <italic>ABCC2</italic> [<xref ref-type="bibr" rid="B51-ijerph-13-01096">51</xref>].</p>
<p>Multidrug resistance-associated protein 4 (MRP4/ABCC4) is involved in the transport of endogenous and xenobiotic organic anionic compounds. Borel and colleagues found that miR-125a/b could regulate <italic>ABCC4</italic> mRNA expression by direct targeting 19 paired HCC tissue [<xref ref-type="bibr" rid="B52-ijerph-13-01096">52</xref>]. More recently, miR-124a and miR-506 were reported to decrease protein levels and function of ABCC4 in HEK293T/17 cells [<xref ref-type="bibr" rid="B53-ijerph-13-01096">53</xref>]. Furthermore, a negative correlation between miR-124a and miR-506 expression and MRP4 protein expression was observed in 26 human kidney samples [<xref ref-type="bibr" rid="B53-ijerph-13-01096">53</xref>].</p>
<p>Borel et al., observed an inverse correlation between ABC transporters and miRNA expression levels in the HCC tissues, and 13 miRNAs were confirmed to target <italic>ABCA1</italic>, <italic>ABCC1</italic>, <italic>ABCC5</italic>, <italic>ABCC10</italic> and <italic>ABCE1</italic> directly [<xref ref-type="bibr" rid="B52-ijerph-13-01096">52</xref>]. The expression of miR-128 was reduced accompanying by ABCC5 overexpression in chemoresistant breast tumor-initiating cells, which may partially explain why reduced miR-128 expression was associated with chemotherapeutic resistance and poor survival in breast cancer [<xref ref-type="bibr" rid="B54-ijerph-13-01096">54</xref>].</p>
<p>Breast cancer resistance protein (BCRP/ABCG2) was initially discovered in multidrug resistant breast cancer cell lines, where it confers resistance to several chemotherapeutic agents. Substrates for ABCG2 include mitoxantrone, topotecan, irinotecan, methotrexate, and tyrosine kinase inhibitors such as imatinib and gefitinib [<xref ref-type="bibr" rid="B55-ijerph-13-01096">55</xref>]. ABCG2 was supposed to contribute to xenobiotica protection for stem cells and underlies the ability of cancer cells to regenerate post-chemotherapy [<xref ref-type="bibr" rid="B56-ijerph-13-01096">56</xref>]. MiR-328 and miR-519c were observed to suppress ABCG2 protein expression by targeting the <italic>ABCG2</italic> 3’-UTR [<xref ref-type="bibr" rid="B57-ijerph-13-01096">57</xref>,<xref ref-type="bibr" rid="B58-ijerph-13-01096">58</xref>,<xref ref-type="bibr" rid="B59-ijerph-13-01096">59</xref>]. Subsequently, Li and colleagues showed that miR-519c downregulates ABCG2 protein expression with accelerating <italic>ABCG2</italic> mRNA degradation and overexpression of miR-519c or miR-328 in MCF-7 cells could increase intracellular mitoxantrone accumulation, which is probably due to a decreased ABCG2 protein expression [<xref ref-type="bibr" rid="B60-ijerph-13-01096">60</xref>]. In chronic myeloid leukemia K-562 cells, short-term imatinib treatment induced ABCG2 expression and decreased miR-212 expression, while anti-miR-212 upregulated ABCG2 protein expression by direct targeting <italic>ABCG2</italic> 3’-UTR [<xref ref-type="bibr" rid="B61-ijerph-13-01096">61</xref>]. Two separate groups have demonstrated that miR-520h can regulate ABCG2 expression by direct inhibition [<xref ref-type="bibr" rid="B62-ijerph-13-01096">62</xref>,<xref ref-type="bibr" rid="B63-ijerph-13-01096">63</xref>]. In addition, miR-181a and miR-487a can sensitize mitoxantone-resistant breast cancer cells to chemotherapeutic agents by targeting <italic>ABCG2</italic> [<xref ref-type="bibr" rid="B64-ijerph-13-01096">64</xref>,<xref ref-type="bibr" rid="B65-ijerph-13-01096">65</xref>].</p>
<p>SLC6A4, also known as serotonin transporter (SERT), is involved in serotonin reuptake. It is the pharmacological target of selective serotonin reuptake inhibitor antidepressants [<xref ref-type="bibr" rid="B66-ijerph-13-01096">66</xref>]. Data from Baudry and colleagues suggested that miR-16 could target <italic>SLC6A4</italic> in neuronal 1C11 cell line [<xref ref-type="bibr" rid="B66-ijerph-13-01096">66</xref>]. In mice, chronic fluoxetine treatment can increase miR-16 levels in serotonergic raphe nuclei, which subsequently downregulate SLC6A4 expression [<xref ref-type="bibr" rid="B66-ijerph-13-01096">66</xref>]. The expression of miR-16 was negatively correlated with SLC6A4 expression in mouse and miR-16 overexpression lead to decrease of SLC6A4 in human alveolar epithelial cells [<xref ref-type="bibr" rid="B67-ijerph-13-01096">67</xref>]. Furthermore, miR-15a and miR-16 could regulate SLC6A4 expression in human placental choriocarcinoma and rat brain raphe cells [<xref ref-type="bibr" rid="B68-ijerph-13-01096">68</xref>].</p>
<p>SLC7A5 is also known as L-type amino acid transporter 1 (LAT1). MiR-126 was reported to inhibit proliferation of small cell lung cancer cells by targeting <italic>SLC7A5</italic> [<xref ref-type="bibr" rid="B69-ijerph-13-01096">69</xref>]. Drayton and colleagues found that miR-27a suppresses protein expression of cystine/glutamate transporter SLC7A11 in cisplatin-resistant bladder cancer. Bladder cancer with low miR-27a or high SLC7A11 expression exhibited poorer clinical outcomes [<xref ref-type="bibr" rid="B70-ijerph-13-01096">70</xref>].</p>
<p>Data from Gillen and colleagues has shown that miR-384, miR-494, and miR-1246 could directly repress mRNA expression of Na-K-Cl co-transporter SLC12A2 in epithelial cells [<xref ref-type="bibr" rid="B71-ijerph-13-01096">71</xref>]. The peptide transporter 1 (PEPT1/SLC15A1) is involved in intestinal absorption of small peptides and a variety of peptidemimetic drugs such as β-lactam antibiotics. MiR-92b was reported to directly downregulate mRNA and protein levels of SLC15A1 and thus reduces SLC15A1-mediated drug transport activity [<xref ref-type="bibr" rid="B72-ijerph-13-01096">72</xref>]. The H-linked monocarboxylate transporter isoform 1 (MCT1/SLC16A1) is involved in the transportation of metabolically important monocarboxylates such as lactate, pyruvate, acetate and ketone bodies. Evidence shows that miR-124 could negatively regulate SLC16A1 expression at both mRNA and protein levels [<xref ref-type="bibr" rid="B73-ijerph-13-01096">73</xref>,<xref ref-type="bibr" rid="B74-ijerph-13-01096">74</xref>].</p>
<p>Up to date, most studies regarding miRNA-mediated regulation of drug transporters mainly focused on MDR in cancer cells [<xref ref-type="bibr" rid="B8-ijerph-13-01096">8</xref>]. Targeting specific miRNAs of the drug-resistant network is promising in overcoming drug resistance in cancer therapy. The miRNA-mediated modification of drug transporters and the clinical relevance requires further investigation.</p>
</sec>
<sec id="sec3dot3-ijerph-13-01096">
<title>3.3. Indirect Regulation of DMEs and Drug Transporters by miRNAs</title>
<p>The expression of genes involved in the disposition of drugs is largely regulated by transcription factors belonging to the xenobiotic-sensing nuclear receptors family such as pregnane X receptor (PXR), constitutive androstane receptor (CAR), and hepatocyte nuclear factor 4 alpha (HNF4α). Nuclear receptors are important in regulation of both the constitutive and inducible expression of DMEs and transporters. MiRNA-mediated regulation of the expression of nuclear receptors becomes potential mechanism for controlling DMEs and transporters.</p>
<p>HNF4α is a key transcription factor that regulates the expression of numerous DMEs and drug transporters such as CYPs, UDP-glucuronosyltransferases (UGTs), ABC transporters, OATs, and OATPs [<xref ref-type="bibr" rid="B75-ijerph-13-01096">75</xref>]. It was found that miR-24 suppresses <italic>HNF4α</italic> mRNA expression mainly through mediating its mRNA degradation, while miR-34a acts through direct translational repression [<xref ref-type="bibr" rid="B76-ijerph-13-01096">76</xref>]. Overexpression of miR-24 and miR-34a resulted in decreased HNF4α protein level and its subsequent targets such as CYP7A1 and CYP8B1 in HepG2 cells [<xref ref-type="bibr" rid="B76-ijerph-13-01096">76</xref>]. Further study showed that HNF4α protein levels were reduced by transfection of miR-24 and miR-629 mimics in HepG2 cells [<xref ref-type="bibr" rid="B77-ijerph-13-01096">77</xref>]. Also, miR-34a and miR-449a could downregulate HNF4α protein expression and <italic>PXR</italic> mRNA levels [<xref ref-type="bibr" rid="B78-ijerph-13-01096">78</xref>]. In addition, overexpression of miR-34a, miR-34c-5p and miR-449a lead to decrease in the protein levels and binding activity of HNF4α [<xref ref-type="bibr" rid="B79-ijerph-13-01096">79</xref>].</p>
<p>PXR is an important xenoreceptor regulating the inducible expression of a variety of transporters and DMEs, including CYP3A4. It was reported that miR-148 directly inhibits PXR protein expression and negatively regulates the translational efficiency of <italic>PXR</italic> in 25 human liver samples [<xref ref-type="bibr" rid="B80-ijerph-13-01096">80</xref>]. MiR-148a could also inhibit the constitutive/inducible <italic>CYP3A4</italic> mRNA expression in a PXR-dependent manner [<xref ref-type="bibr" rid="B80-ijerph-13-01096">80</xref>]. However, subsequent study failed to observe the correlation between miR-148 and protein and mRNA level of PXR or CYP3A4 in human liver samples [<xref ref-type="bibr" rid="B10-ijerph-13-01096">10</xref>,<xref ref-type="bibr" rid="B81-ijerph-13-01096">81</xref>].</p>
<p>Vitamin D receptor (VDR) is a nuclear hormone receptor, which functions as transcription factors by binding to vitamin D response element in the promoters of the target genes, such as <italic>CYP3A4</italic> [<xref ref-type="bibr" rid="B82-ijerph-13-01096">82</xref>]. MiR-27b was found to indirectly regulate CYP3A4 by indirect targeting the <italic>VDR</italic> 3’-UTR and by direct targeting [<xref ref-type="bibr" rid="B23-ijerph-13-01096">23</xref>]. Furthermore, miR-125b could decrease VDR protein level in MCF-7 cells by binding to recognition element within <italic>VDR</italic> 3’UTR [<xref ref-type="bibr" rid="B30-ijerph-13-01096">30</xref>]. Hence, miR-125b may be supposed to indirectly influence CYP3A4 via VDR mediated posttranscriptional regulation.</p>
<p>Glucocorticoids such as cortisol exhibit profound role in neuronal development, immunity, and metabolism by binding to the glucocorticoid receptor (GR) [<xref ref-type="bibr" rid="B83-ijerph-13-01096">83</xref>]. It was found that GR could regulate the expression of CYP2C and CYP3A4 [<xref ref-type="bibr" rid="B84-ijerph-13-01096">84</xref>]. Vreugdenhil et al., demonstrated that miR-18 and miR-124a decreased GR-mediated events in addition to reducing GR protein levels in neuronal tissues [<xref ref-type="bibr" rid="B85-ijerph-13-01096">85</xref>]. However, the miRNA-mediated posttranscriptional regulation of GR exhibits no correlation with xenobiotic biotransformation.</p>
<p>Estrogen receptor 1 (ESR1), an estrogen-activated nuclear receptors, is involved in regulation of CYP1B1 expression. Data form Adams and colleagues demonstrated that miR-206 suppresses ESR1 mRNA and protein level in breast cancer cell lines [<xref ref-type="bibr" rid="B86-ijerph-13-01096">86</xref>]. MiR-221 and miR-222 suppress ESR1 protein level in MCF-7 and T47D cells [<xref ref-type="bibr" rid="B87-ijerph-13-01096">87</xref>]. Overexpression of miR-221 or miR-222 resulted in the breast cancer cell line becoming resistant to tamoxifen [<xref ref-type="bibr" rid="B87-ijerph-13-01096">87</xref>]. Also, miR-22 directly inhibited ESR1 mRNA and protein expression in breast cancer cell lines and clinical biopsies [<xref ref-type="bibr" rid="B88-ijerph-13-01096">88</xref>,<xref ref-type="bibr" rid="B89-ijerph-13-01096">89</xref>]. In addition, ESR1 was a direct target of miR-130a in HepG2.2.15 human HCC cells [<xref ref-type="bibr" rid="B90-ijerph-13-01096">90</xref>].</p>
<p>Peroxisome proliferator activated receptor alpha (PPARα) is a nuclear hormone receptor family transcription factor, which is involved in regulation of DME and tumor progression. MiR-10b was proven to inhibit PPARα protein expression in steatotic L02 cells [<xref ref-type="bibr" rid="B91-ijerph-13-01096">91</xref>]. Also, miR-21 and miR-27b could regulate PPARα protein level in Huh7 cells [<xref ref-type="bibr" rid="B92-ijerph-13-01096">92</xref>]. However, these miRNAs exhibited no effect on <italic>PPARα</italic> mRNA levels. Tong et al., showed that miR-506 overexpression in a colon cancer cell could inhibit PPARα expression, which resulted in hydroxycamptothecin resistance [<xref ref-type="bibr" rid="B93-ijerph-13-01096">93</xref>]. Another nuclear receptor liver X receptor α (LXRα) has been found to be suppressed by miR-613 in HepG2 cells [<xref ref-type="bibr" rid="B94-ijerph-13-01096">94</xref>,<xref ref-type="bibr" rid="B95-ijerph-13-01096">95</xref>]. A recent study revealed that miR-206 inhibits LXRα protein expression and promotes LXR-mediated cholesterol efflux in macrophages [<xref ref-type="bibr" rid="B96-ijerph-13-01096">96</xref>].</p>
</sec>
<sec id="sec3dot4-ijerph-13-01096">
<title>3.4. MiRNAs Mediate Drug-Drug Interactions in Pharmacokinetics</title>
<p>Xenobiotic agent induced dysregulation of miRNAs, which regulates the expression of DEMs and drug transports, may result in considerable alterations in the pharmacokinetic profile of a concomitant drug [<xref ref-type="bibr" rid="B97-ijerph-13-01096">97</xref>]. Rodrigues et al., revealed that the expression of several miRNAs (miR-27a, miR-124a, miR-148a, and miR-451) in MCF-7, Caco-2, SH-SY5Y and BE(2)-M17 cell lines can be influenced by exposure to 19 xenobiotic drugs, including methadone, dexamethasone, gemcitabine, imatinib, and mitoxantrone [<xref ref-type="bibr" rid="B98-ijerph-13-01096">98</xref>]. In this respect, the upregulation of CYP3A4 and ABCB1 by dexamethasone may involve the suppression of dexamethasone on miR-27b, miR-148a and miR-451 [<xref ref-type="bibr" rid="B98-ijerph-13-01096">98</xref>], which could target 3’-UTR of <italic>CYP3A4</italic> and <italic>ABCB1</italic>. Moreover, bilobalide led to a decreased level of miR-148a [<xref ref-type="bibr" rid="B98-ijerph-13-01096">98</xref>], which could directly inhibit PXR protein expression. Neuronal miR-124a was reduced by treatment with psychoactive drugs (cocaine, methadone and fluoxetine) [<xref ref-type="bibr" rid="B98-ijerph-13-01096">98</xref>], which may provide increased understanding of neuroplasticity. Dysregulated expression of miR-10a, miR-146a, miR-200b, miR-200c, miR-221/222, and miR-345 induced by drugs could result in chemoresistance to cisplatin in MCF-7 breast cancer cells [<xref ref-type="bibr" rid="B99-ijerph-13-01096">99</xref>].</p>
<p>Rifampicin is a well-known drug inducer that activates PXR/RXR. The induction of <italic>MDR1</italic> and <italic>CYP2B6</italic> mRNA by rifampicin are attenuated by miR-148a overexpression in LS180 cells [<xref ref-type="bibr" rid="B80-ijerph-13-01096">80</xref>]. Rifampicin could downregulate ABCC2 protein expression by increasing miR-379 expression in HepG2 cells [<xref ref-type="bibr" rid="B48-ijerph-13-01096">48</xref>]. In primarily cultured hepatocytes, rifampicin upregulated and downregulated the expression of a set of miRNAs, and some of the mRNA/miRNA pairs were inversely associated [<xref ref-type="bibr" rid="B100-ijerph-13-01096">100</xref>,<xref ref-type="bibr" rid="B101-ijerph-13-01096">101</xref>]. Hence, delineation of the influence of xenobiotic drugs on miRNA profile might present a mechanism of altered gene expression underlying drug disposition and drug-drug interaction.</p>
</sec>
</sec>
<sec id="sec4-ijerph-13-01096">
<title>4. MiRSNPs Modify Cancer Chemotherapy Response and Survival</title>
<p>A class of functional polymorphisms termed miRNA polymorphisms or miRSNPs are reported to be a new player in miRNA-mediated gene regulation (<xref ref-type="fig" rid="ijerph-13-01096-f002">Figure 2</xref>). MiRSNPs refer to polymorphisms present at or near miRNA binding sites of functional genes as well as in genes involved in miRNA biogenesis and in pri-, pre- and mature miRNA sequences. A growing number of miRNAs related causative SNPs were identified [<xref ref-type="bibr" rid="B102-ijerph-13-01096">102</xref>]. Disease susceptibility associated miRSNPs have attracted growing interests [<xref ref-type="bibr" rid="B103-ijerph-13-01096">103</xref>]. However, knowledge about the pharmacogenomic significance of the miRSNPs is scarce. Most interest in miRSNPs is focused on cancer chemotherapy resistance and survival. Numerous miRSNPs associated with chemotherapy response and clinical outcomes are identified (<xref ref-type="table" rid="ijerph-13-01096-t002">Table 2</xref>).</p>
<sec id="sec4dot1-ijerph-13-01096">
<title>4.1. MiRNA Target Site Polymorphisms</title>
<p>Lung cancer (LC) is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for 80% of all lung cancer cases and less than 15% of patients with NSCLC survive beyond 5 years [<xref ref-type="bibr" rid="B104-ijerph-13-01096">104</xref>]. Thus, identification of specific prognostic biomarkers may improve the medical care of patients with NSCLC. Increased SET8 expression was observed in various types of tumor, including LC. <italic>SET8</italic> rs2240688 T &gt; C, a polymorphism within miR-502 binding site, was reported to be associated with increased overall survival (OS) or reduced risk of death in small-cell lung cancer (SCLC) [<xref ref-type="bibr" rid="B105-ijerph-13-01096">105</xref>] and NSCLC [<xref ref-type="bibr" rid="B106-ijerph-13-01096">106</xref>]. SET8 modifies cancer prognosis by altering its expression, which could be suppressed by miR-502. Another miRSNP, rs2240688 A &gt; C, within the 3′-UTR of <italic>CD133</italic> was associated with favorable prognosis [<xref ref-type="bibr" rid="B107-ijerph-13-01096">107</xref>]. Functional assays revealed that rs2240688 C allele creates a new binding site for miR-135a/b and thus reduced <italic>CD133</italic> mRNA level [<xref ref-type="bibr" rid="B107-ijerph-13-01096">107</xref>]. CD133 was overexpressed in several human cancer tissues and was associated with poor prognosis [<xref ref-type="bibr" rid="B107-ijerph-13-01096">107</xref>]. In another study on NSCLC, <italic>KTR81</italic> rs3660 polymorphism within potential miR-17 target site was associated with increased time to recurrence of NSCLC [<xref ref-type="bibr" rid="B108-ijerph-13-01096">108</xref>]. In addition, evidence revealed that <italic>FAS</italic> rs2234978 common allele was associated with longer OS of NSCLC [<xref ref-type="bibr" rid="B109-ijerph-13-01096">109</xref>]. In the same study, the G allele of <italic>FZD4</italic> rs713065 was associated with longer OS of early NSCLC [<xref ref-type="bibr" rid="B109-ijerph-13-01096">109</xref>]. Luciferase reporter assays showed that minor allele of rs2234978 and rs713065 created binding site for miR-651 and miR-204 [<xref ref-type="bibr" rid="B109-ijerph-13-01096">109</xref>,<xref ref-type="bibr" rid="B110-ijerph-13-01096">110</xref>].</p>
<p>Colorectal cancer (CRC) is the second most common malignancy and the fourth-leading cause of cancer death worldwide. Evidences revealed that miRSNPs may represent prognosis markers of CRC. The variant allele of LCS6 polymorphism (rs61764370 T &gt; G) in the binding site of let-7 to <italic>KRAS</italic> 3’-UTR was reported to be associated with reduced OS and progression-free survival (PFS) in metastatic colorectal cancer (mCRC) [<xref ref-type="bibr" rid="B111-ijerph-13-01096">111</xref>], and nonresponse to anti-EGFR-based treatment in <italic>KRAS</italic> and <italic>BRAF</italic> wild-type mCRC patients [<xref ref-type="bibr" rid="B112-ijerph-13-01096">112</xref>]. However, the conflict results were also observed, in which LCS6 common allele exhibited association with shorter PFS/OS or no effect on them [<xref ref-type="bibr" rid="B113-ijerph-13-01096">113</xref>,<xref ref-type="bibr" rid="B114-ijerph-13-01096">114</xref>]. The contradictions may be explained by small sample size and the different inclusion criteria for the mutations in each study. Further clinical studies are needed to increase the accuracy in predicting cetuximab responsiveness based on the LCS6 polymorphism.</p>
<p>Ovarian cancer (OC) is the most lethal gynecological malignancy and the 5-year survival rate is less than 30% [<xref ref-type="bibr" rid="B115-ijerph-13-01096">115</xref>]. A recent study revealed that variant allele of <italic>MDM4</italic> 3’-UTR polymorphism rs4245739 abrogates the miR-191 target site and results in increased MDM4 expression, which was associated with increased risk for recurrence, accelerated tumor progression, and chemotherapy resistance in ovarian carcinoma [<xref ref-type="bibr" rid="B115-ijerph-13-01096">115</xref>]. In a study on 417 Caucasian patients with OC, another potential miR-409-3p recognition site polymorphism, <italic>MDM4</italic> rs10900596 G &gt; A, was related to an improved treatment response in ovarian cancer [<xref ref-type="bibr" rid="B116-ijerph-13-01096">116</xref>]. In the same study, the rs1425486 variant allele disrupts <italic>PDGFC</italic> pairing with miR-425, inhibits miR-425 targeting, and results in higher PDGFC expression and worse OS [<xref ref-type="bibr" rid="B116-ijerph-13-01096">116</xref>]. Moreover, the variant allele of <italic>KRAS</italic> rs10771184 within potential miR-544 binding site was associated with better treatment response and increased OS in OC [<xref ref-type="bibr" rid="B116-ijerph-13-01096">116</xref>].</p>
<p>Several miRSNPs exhibited association with survival of other tumors. The rs2240688 CC genotype was identified to be associated with reduced SET8 protein levels and longer postoperative OS in Asian patients with HCC [<xref ref-type="bibr" rid="B117-ijerph-13-01096">117</xref>]. The results suggest that SET8 modifies cancer prognosis by altering its expression, which could be suppressed by miR-502. Evidence indicates that <italic>KTR81</italic> rs3660 polymorphism within potential miR-17 target site was associated with toxicity or survival of Hodgkin lymphoma [<xref ref-type="bibr" rid="B118-ijerph-13-01096">118</xref>] and multiple myeloma [<xref ref-type="bibr" rid="B119-ijerph-13-01096">119</xref>]. Furthermore, the rs1045385 C allele of <italic>AP-2α</italic> rs1045385 polymorphism was insensitive to miR-200b/200c/429 induced repression of AP-2α expression and increases cisplatin sensitivity in endometrial cancer cell line HEC-1A cells [<xref ref-type="bibr" rid="B120-ijerph-13-01096">120</xref>]. In addition, the <italic>CDON</italic> rs3737336 polymorphism located in the miR-181c/miR-5007 binding site was associated with reduced PFS of prostate cancer [<xref ref-type="bibr" rid="B121-ijerph-13-01096">121</xref>,<xref ref-type="bibr" rid="B122-ijerph-13-01096">122</xref>].</p>
</sec>
<sec id="sec4dot2-ijerph-13-01096">
<title>4.2. Polymorphisms in miRNA Biogenesis Gene</title>
<p>Numerous miRSNPs associated with NSCLC chemotherapy toxicity or survival were identified. <italic>MiR-196a2</italic> rs11614913 C &gt; T polymorphism could alter mature miRNA expression and function. Rs11614913 CC homozygotes exhibited higher occurrence of overall toxicity in response to gemcitabine or cisplatin [<xref ref-type="bibr" rid="B123-ijerph-13-01096">123</xref>]. Also, rs11614913 T allele was associated with better OS and disease-free survival (DFS) [<xref ref-type="bibr" rid="B124-ijerph-13-01096">124</xref>]. In the same study, the minor allele carriers of <italic>miR-149</italic> rs2292832 exhibited better OS and DFS [<xref ref-type="bibr" rid="B124-ijerph-13-01096">124</xref>]. Recent evidence indicated that G allele of <italic>pre-miR-27a</italic> rs895819 was associated with decreased response rate to platinum-based chemotherapy, reduced OS and increased risk of death in NSCLC [<xref ref-type="bibr" rid="B125-ijerph-13-01096">125</xref>]. In another study on 452 early-stage and 526 late-stage NSCLC patients, minor allele of <italic>miR-5197</italic> rs2042253 was associated with increased OS [<xref ref-type="bibr" rid="B126-ijerph-13-01096">126</xref>]. Recently, <italic>DROSHA</italic> rs6886834 minor allele was associated with shorter median recurrence-free time [<xref ref-type="bibr" rid="B109-ijerph-13-01096">109</xref>]. Furthermore, <italic>XPO5</italic> 3’-UTR polymorphism rs11077 was identified as predictor for recurrence of NSCLC [<xref ref-type="bibr" rid="B108-ijerph-13-01096">108</xref>] and survival of SCLC [<xref ref-type="bibr" rid="B127-ijerph-13-01096">127</xref>].</p>
<p>There are several miRSNPs as markers of clinical outcome of CRC. Boni et al., found two polymorphisms were associated with clinical outcome in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan [<xref ref-type="bibr" rid="B128-ijerph-13-01096">128</xref>]. The rare homozygous genotype of <italic>pri-miR26a-1</italic> rs7372209 exhibited poorer response and reduced time to progression [<xref ref-type="bibr" rid="B128-ijerph-13-01096">128</xref>]. And the minor allele of another polymorphism <italic>pri-miR-100</italic> rs1834306 was associated with increased time to progression [<xref ref-type="bibr" rid="B128-ijerph-13-01096">128</xref>]. The minor allele of <italic>miR-608</italic> rs4919510 was associated with shorter recurrence-free survival (RFS) and the minor allele homozygotes in <italic>miR-219-1</italic> rs213210 exhibited increased RFS of colorectal adenocarcinoma [<xref ref-type="bibr" rid="B129-ijerph-13-01096">129</xref>]. Recently, major allele in <italic>miR-219-1</italic> rs213210 was reported to be associated with worse OS [<xref ref-type="bibr" rid="B130-ijerph-13-01096">130</xref>]. In the same study, carriers of minor allele in <italic>miR-608</italic> rs4919510 exhibited longer event-free survival (EFS) [<xref ref-type="bibr" rid="B130-ijerph-13-01096">130</xref>].</p>
<p>Evidences have shown that miRSNPs may be associated with survival in urinary system cancers. Two miRSNPs, <italic>KIF3C</italic> rs6728684 and <italic>IFI30</italic> rs1045747, were associated with reduced PFS in prostate cancer treated with androgen-deprivation therapy [<xref ref-type="bibr" rid="B121-ijerph-13-01096">121</xref>]. The variant allele of <italic>DDX20</italic> rs197412 conferred a decreased risk of recurrence and the variant homozygous genotype of <italic>DGCR8</italic> rs2073778 was associated with increased risk of progression in non-muscle-invasive bladder cancer [<xref ref-type="bibr" rid="B131-ijerph-13-01096">131</xref>].</p>
<p>MiRSNPs were also identified as prognostic markers for other cancers. <italic>XPO5</italic> rs11077 polymorphism exhibited association with OS and PFS of multiple myeloma [<xref ref-type="bibr" rid="B119-ijerph-13-01096">119</xref>], chemotherapy toxicity and OS of Hodgkin lymphoma [<xref ref-type="bibr" rid="B118-ijerph-13-01096">118</xref>], and survival of HCC [<xref ref-type="bibr" rid="B132-ijerph-13-01096">132</xref>]. In addition, the G allele of rs17408716 within <italic>RNASEN</italic> was associated with better treatment response and longer OS of OC [<xref ref-type="bibr" rid="B116-ijerph-13-01096">116</xref>].</p>
</sec>
<sec id="sec4dot3-ijerph-13-01096">
<title>4.3. CNV-miRNA: Possible Causative Variations Affecting Drug Response</title>
<p>Copy number variations (CNVs) refer to segments of genomic DNA that show variable numbers of copies in the genome due to deletions or duplications. CNVs affect gene expression in a copy number-dependent manner and account for about 18% detected genetic variation in gene expression [<xref ref-type="bibr" rid="B133-ijerph-13-01096">133</xref>]. CNVs in miRNA genes (CNV-miRNAs) affect binding and regulation of miRNA target genes [<xref ref-type="bibr" rid="B134-ijerph-13-01096">134</xref>]. Evidences have revealed that CNV-miRNAs were involved in a broad range of phenotypes, including male fertility [<xref ref-type="bibr" rid="B135-ijerph-13-01096">135</xref>], multiple sclerosis [<xref ref-type="bibr" rid="B136-ijerph-13-01096">136</xref>], and autism [<xref ref-type="bibr" rid="B137-ijerph-13-01096">137</xref>]. More recently, 209 CNV-miRNAs were identified in CNV regions, and 4 miRNAs (miR-1268, miR-1233, miR-1972, and miR-384) were located in polymorphic CNV regions [<xref ref-type="bibr" rid="B138-ijerph-13-01096">138</xref>]. These miRNA-CNVs include deletions (miR-384 and miR-1324), duplications (miR-1972 and miR-1977), and multiple duplications (miR-1233 and miR-1268) [<xref ref-type="bibr" rid="B138-ijerph-13-01096">138</xref>]. Significance of these miRNA-CNVs remains to be explored. Therefore, there is still a long way to go before the implication of these miR-CNVs into pharmacogenomics and personalized medicine.</p>
</sec>
</sec>
<sec id="sec5-ijerph-13-01096">
<title>5. MiRNAs and Ethnic Difference in Drug Response</title>
<p>Evidences revealed that polymorphisms in miRNAs have significantly different frequencies among various populations [<xref ref-type="bibr" rid="B139-ijerph-13-01096">139</xref>,<xref ref-type="bibr" rid="B140-ijerph-13-01096">140</xref>]. And these polymorphisms may lead to severe defects to functions of miRNAs and then possible ethnic difference in drug response. Previous studies have demonstrated that 17%–30% of genes are differentially expressed among different ethnic populations [<xref ref-type="bibr" rid="B140-ijerph-13-01096">140</xref>,<xref ref-type="bibr" rid="B141-ijerph-13-01096">141</xref>] and miRNAs are also expressed in a population-specific manner [<xref ref-type="bibr" rid="B141-ijerph-13-01096">141</xref>,<xref ref-type="bibr" rid="B142-ijerph-13-01096">142</xref>]. The differentially expressed genes and miRNAs may be another basis of ethnic difference in drug response.</p>
<p>A total of 1899 SNPs in 961 reported pre-miRNAs were identified [<xref ref-type="bibr" rid="B139-ijerph-13-01096">139</xref>]. Among them, some SNPs exhibited significantly different frequencies between various populations in the HapMap and 1000 Genome Projects [<xref ref-type="bibr" rid="B139-ijerph-13-01096">139</xref>]. Recently, Rawlings-Goss et al., identified 31 miRSNPs that were globally population-differentiated in frequency between African and non-African populations [<xref ref-type="bibr" rid="B140-ijerph-13-01096">140</xref>]. Moreover, miR-202, a potential breast cancer biomarker, exhibited significantly high allele frequency differentiation at rs12355840 polymorphism, which influences miRNA expression in vivo and breast cancer mortality [<xref ref-type="bibr" rid="B140-ijerph-13-01096">140</xref>]. The role of these SNPs in the inter-ethnic difference in drug response needs further investigation.</p>
<p>Previous studies identified many miRNAs that exhibit ethnic difference in expression and prognostic significance for cancer. A total of 33 differentially expressed miRNAs between CEU and YRI were identified in HapMap lymphoblastoid cell lines [<xref ref-type="bibr" rid="B142-ijerph-13-01096">142</xref>]. More than 55% of the differentially expressed miRNAs were inversely correlated with an mRNA expression phenotype in each population samples, and 21 of these miRNAs correlated with cellular sensitivity to at least one of the chemotherapeutic agents in carboplatin, daunorubicin, and cytarabine [<xref ref-type="bibr" rid="B142-ijerph-13-01096">142</xref>]. Moreover, a large number of SNPs exhibiting different allele frequencies affected the expression of the differentially expressed miRNAs [<xref ref-type="bibr" rid="B142-ijerph-13-01096">142</xref>]. High miR-181b expression in cancer tissue correlated with poor survival of black rather than white patients with CRC [<xref ref-type="bibr" rid="B143-ijerph-13-01096">143</xref>]. The expression levels of plasma miR-375 are ethnically different in diabetes of Han and Kazak populations [<xref ref-type="bibr" rid="B144-ijerph-13-01096">144</xref>]. Furthermore, higher plasma miR-144 expression was significantly associated with diabetes in Swedes, but not in Iraqis [<xref ref-type="bibr" rid="B145-ijerph-13-01096">145</xref>]. MiR-182, miR-152, miR-204, miR-222 and miR-202 exhibited differential expression in colon cancer between African and Caucasian Americans [<xref ref-type="bibr" rid="B146-ijerph-13-01096">146</xref>]. Notably, miR-182 was increased and two potential miR-182 targets (<italic>FOXO1</italic> and <italic>FOXO3A</italic>) were decreased in African Americans tumors, which may contribute to decreased colon cancer survival in African Americans [<xref ref-type="bibr" rid="B146-ijerph-13-01096">146</xref>].</p>
</sec>
<sec id="sec6-ijerph-13-01096">
<title>6. Conclusions</title>
<p>MiRNAs emerge as a new player in epigenetic regulation of genes involved in drug response. MiRSNPs are recently found to be associated with progression and prognosis of different types of cancers. Detection of miRNAs and miRSNPs holds promise in the field of miRNA pharmacogenomics for individualized medicine. The challenge for achieving individualized drug therapy is manyfold. Establishing the relation of miRNAs and miRSNPs to drug response phenotypes may not be straightforward. Factors affecting drug response are multifold and complex. At present, individualized drug therapy may be achieved when these factor are simple and well defined. Several important achievements, such as warfarin therapy based on <italic>VKORC1</italic> and <italic>CYP2C9</italic> genotypes, have been achieved. Large scale, prospective clinical trials are needed to reveal causal associations between genetic as well as epigenetic variations and drug response. It is safe to say that more pharmacoepigenomic biomarker of drug response and stronger supporting clinical research evidence are expected to surface in the coming years.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This study was supported by National Science and Technology Major Project (2013ZX09509107), National Natural Science Foundation of China (81373489, 81422052, and 81403018), Hunan Provincial Natural Science Foundation of China (13JJ1010 and 2015JJ3169), Funds of Hunan Provincial Education Department (12K006), and Fundamental Research Funds for the Central Universities of Central South University (2014zzts073).</p>
</ack>
<notes>
<title>Author Contributions</title>
<p>Mu-Peng Li, Jie Tang, and Xiao-Ping Chen were responsible for the concept of the review; Mu-Peng Li and Jie Tang drafted the manuscript; Yao-Dong Hu, Xiao-Lei Hu, Yan-Jiao Zhang, Yong-Long Yang, Chun Jiang, and Xiao-Ping Chen provided a critical review of the manuscript. All authors contributed to and agreed on the final version of the manuscript.</p>
</notes>
<notes notes-type="COI-statement">
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</notes>
<ref-list>
<title>References</title>
<ref id="B1-ijerph-13-01096">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baer-Dubowska</surname><given-names>W.</given-names></name><name><surname>Majchrzak-Celinska</surname><given-names>A.</given-names></name><name><surname>Cichocki</surname><given-names>M.</given-names></name></person-group>
<article-title>Pharmocoepigenetics: A new approach to predicting individual drug responses and targeting new drugs</article-title>
<source/>Pharmacol. Rep.
<year>2011</year>
<volume>63</volume>
<fpage>293</fpage>
<lpage>304</lpage>
<pub-id pub-id-type="doi">10.1016/S1734-1140(11)70498-4</pub-id>
<pub-id pub-id-type="pmid">21602587</pub-id></element-citation>
</ref>
<ref id="B2-ijerph-13-01096">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakajima</surname><given-names>M.</given-names></name><name><surname>Yokoi</surname><given-names>T.</given-names></name></person-group>
<article-title>MicroRNAs from biology to future pharmacotherapy: Regulation of cytochrome P450s and nuclear receptors</article-title>
<source/>Pharmacol. Ther.
<year>2011</year>
<volume>131</volume>
<fpage>330</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2011.04.009</pub-id>
<pub-id pub-id-type="pmid">21565218</pub-id></element-citation>
</ref>
<ref id="B3-ijerph-13-01096">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cascorbi</surname><given-names>I.</given-names></name></person-group>
<article-title>Overlapping effects of genetic variation and epigenetics on drug response: Challenges of pharmacoepigenomics</article-title>
<source/>Pharmacogenomics
<year>2013</year>
<volume>14</volume>
<fpage>1807</fpage>
<lpage>1809</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.13.194</pub-id>
<pub-id pub-id-type="pmid">24236479</pub-id></element-citation>
</ref>
<ref id="B4-ijerph-13-01096">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rukov</surname><given-names>J.L.</given-names></name><name><surname>Shomron</surname><given-names>N.</given-names></name></person-group>
<article-title>MicroRNA pharmacogenomics: Post-transcriptional regulation of drug response</article-title>
<source/>Trends Mol. Med.
<year>2011</year>
<volume>17</volume>
<fpage>412</fpage>
<lpage>423</lpage>
<pub-id pub-id-type="doi">10.1016/j.molmed.2011.04.003</pub-id>
<pub-id pub-id-type="pmid">21652264</pub-id></element-citation>
</ref>
<ref id="B5-ijerph-13-01096">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fromm</surname><given-names>B.</given-names></name><name><surname>Billipp</surname><given-names>T.</given-names></name><name><surname>Peck</surname><given-names>L.E.</given-names></name><name><surname>Johansen</surname><given-names>M.</given-names></name><name><surname>Tarver</surname><given-names>J.E.</given-names></name><name><surname>King</surname><given-names>B.L.</given-names></name><name><surname>Newcomb</surname><given-names>J.M.</given-names></name><name><surname>Sempere</surname><given-names>L.F.</given-names></name><name><surname>Flatmark</surname><given-names>K.</given-names></name><name><surname>Hovig</surname><given-names>E.</given-names></name><etal></etal></person-group>
<article-title>A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome</article-title>
<source/>Annu. Rev. Genet.
<year>2015</year>
<volume>49</volume>
<fpage>213</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="doi">10.1146/annurev-genet-120213-092023</pub-id>
<pub-id pub-id-type="pmid">26473382</pub-id></element-citation>
</ref>
<ref id="B6-ijerph-13-01096">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Friedman</surname><given-names>R.C.</given-names></name><name><surname>Farh</surname><given-names>K.K.</given-names></name><name><surname>Burge</surname><given-names>C.B.</given-names></name><name><surname>Bartel</surname><given-names>D.P.</given-names></name></person-group>
<article-title>Most mammalian mRNAs are conserved targets of microRNAs</article-title>
<source/>Genome Res.
<year>2009</year>
<volume>19</volume>
<fpage>92</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="doi">10.1101/gr.082701.108</pub-id>
<pub-id pub-id-type="pmid">18955434</pub-id></element-citation>
</ref>
<ref id="B7-ijerph-13-01096">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beermann</surname><given-names>J.</given-names></name><name><surname>Piccoli</surname><given-names>M.T.</given-names></name><name><surname>Viereck</surname><given-names>J.</given-names></name><name><surname>Thum</surname><given-names>T.</given-names></name></person-group>
<article-title>Non-coding RNAs in development and disease: Background, mechanisms, and therapeutic approaches</article-title>
<source/>Physiol. Rev.
<year>2016</year>
<volume>96</volume>
<fpage>1297</fpage>
<lpage>1325</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00041.2015</pub-id>
<pub-id pub-id-type="pmid">27535639</pub-id></element-citation>
</ref>
<ref id="B8-ijerph-13-01096">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Chevillet</surname><given-names>J.R.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>T.K.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name></person-group>
<article-title>The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs</article-title>
<source/>Br. J. Pharmacol.
<year>2015</year>
<volume>172</volume>
<fpage>2733</fpage>
<lpage>2747</lpage>
<pub-id pub-id-type="doi">10.1111/bph.12968</pub-id>
<pub-id pub-id-type="pmid">25296724</pub-id></element-citation>
</ref>
<ref id="B9-ijerph-13-01096">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Oberg</surname><given-names>A.L.</given-names></name><name><surname>Asmann</surname><given-names>Y.W.</given-names></name><name><surname>Sicotte</surname><given-names>H.</given-names></name><name><surname>McDonnell</surname><given-names>S.K.</given-names></name><name><surname>Riska</surname><given-names>S.M.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Steer</surname><given-names>C.J.</given-names></name><name><surname>Subramanian</surname><given-names>S.</given-names></name><name><surname>Cunningham</surname><given-names>J.M.</given-names></name><etal></etal></person-group>
<article-title>Genome-wide transcriptional profiling reveals microRNA-correlated genes and biological processes in human lymphoblastoid cell lines</article-title>
<source/>PLoS ONE
<year>2009</year>
<volume>4</volume>
<elocation-id>e5878</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0005878</pub-id>
<pub-id pub-id-type="pmid">19517021</pub-id></element-citation>
</ref>
<ref id="B10-ijerph-13-01096">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rieger</surname><given-names>J.K.</given-names></name><name><surname>Klein</surname><given-names>K.</given-names></name><name><surname>Winter</surname><given-names>S.</given-names></name><name><surname>Zanger</surname><given-names>U.M.</given-names></name></person-group>
<article-title>Expression variability of absorption, distribution, metabolism, excretion-related microRNAs in human liver: Influence of nongenetic factors and association with gene expression</article-title>
<source/>Drug Metab. Dispos.
<year>2013</year>
<volume>41</volume>
<fpage>1752</fpage>
<lpage>1762</lpage>
<pub-id pub-id-type="doi">10.1124/dmd.113.052126</pub-id>
<pub-id pub-id-type="pmid">23733276</pub-id></element-citation>
</ref>
<ref id="B11-ijerph-13-01096">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi</surname><given-names>Y.M.</given-names></name><name><surname>An</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>E.M.</given-names></name><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Choi</surname><given-names>S.J.</given-names></name><name><surname>Kim</surname><given-names>J.S.</given-names></name><name><surname>Jang</surname><given-names>H.H.</given-names></name><name><surname>An</surname><given-names>I.S.</given-names></name><name><surname>Bae</surname><given-names>S.</given-names></name></person-group>
<article-title>CYP1A1 is a target of miR-892a-mediated post-transcriptional repression</article-title>
<source/>Int. J. Oncol.
<year>2012</year>
<volume>41</volume>
<fpage>331</fpage>
<lpage>336</lpage>
<pub-id pub-id-type="pmid">22470100</pub-id></element-citation>
</ref>
<ref id="B12-ijerph-13-01096">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Tan</surname><given-names>W.</given-names></name><name><surname>Hao</surname><given-names>B.</given-names></name><name><surname>Miao</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>G.</given-names></name><name><surname>He</surname><given-names>F.</given-names></name><name><surname>Lin</surname><given-names>D.</given-names></name></person-group>
<article-title>Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK</article-title>
<source/>Cancer Res.
<year>2003</year>
<volume>63</volume>
<fpage>8057</fpage>
<lpage>8061</lpage>
<pub-id pub-id-type="pmid">14633739</pub-id></element-citation>
</ref>
<ref id="B13-ijerph-13-01096">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalscheuer</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Zeng</surname><given-names>Y.</given-names></name><name><surname>Upadhyaya</surname><given-names>P.</given-names></name></person-group>
<article-title>Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone</article-title>
<source/>Carcinogenesis
<year>2008</year>
<volume>29</volume>
<fpage>2394</fpage>
<lpage>2399</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgn209</pub-id>
<pub-id pub-id-type="pmid">18780894</pub-id></element-citation>
</ref>
<ref id="B14-ijerph-13-01096">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tsuchiya</surname><given-names>Y.</given-names></name><name><surname>Nakajima</surname><given-names>M.</given-names></name><name><surname>Takagi</surname><given-names>S.</given-names></name><name><surname>Taniya</surname><given-names>T.</given-names></name><name><surname>Yokoi</surname><given-names>T.</given-names></name></person-group>
<article-title>MicroRNA regulates the expression of human cytochrome P450 1B1</article-title>
<source/>Cancer Res.
<year>2006</year>
<volume>66</volume>
<fpage>9090</fpage>
<lpage>9098</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-1403</pub-id>
<pub-id pub-id-type="pmid">16982751</pub-id></element-citation>
</ref>
<ref id="B15-ijerph-13-01096">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>I.</given-names></name><name><surname>Mitsui</surname><given-names>Y.</given-names></name><name><surname>Fukuhara</surname><given-names>S.</given-names></name><name><surname>Gill</surname><given-names>A.</given-names></name><name><surname>Wong</surname><given-names>D.K.</given-names></name><name><surname>Yamamura</surname><given-names>S.</given-names></name><name><surname>Shahryari</surname><given-names>V.</given-names></name><name><surname>Tabatabai</surname><given-names>Z.L.</given-names></name><name><surname>Dahiya</surname><given-names>R.</given-names></name><name><surname>Shin</surname><given-names>D.M.</given-names></name><etal></etal></person-group>
<article-title>Loss of miR-200c up-regulates CYP1B1 and confers docetaxel resistance in renal cell carcinoma</article-title>
<source/>Oncotarget
<year>2015</year>
<volume>6</volume>
<fpage>7774</fpage>
<lpage>7787</lpage>
<pub-id pub-id-type="doi">10.18632/oncotarget.3484</pub-id>
<pub-id pub-id-type="pmid">25860934</pub-id></element-citation>
</ref>
<ref id="B16-ijerph-13-01096">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Devlin</surname><given-names>A.H.</given-names></name><name><surname>Thompson</surname><given-names>P.</given-names></name><name><surname>Robson</surname><given-names>T.</given-names></name><name><surname>McKeown</surname><given-names>S.R.</given-names></name></person-group>
<article-title>Cytochrome P450 1B1 mRNA untranslated regions interact to inhibit protein translation</article-title>
<source/>Mol. Carcinogenes.
<year>2010</year>
<volume>49</volume>
<fpage>190</fpage>
<lpage>199</lpage>
<pub-id pub-id-type="doi">10.1002/mc.20589</pub-id>
<pub-id pub-id-type="pmid">19908239</pub-id></element-citation>
</ref>
<ref id="B17-ijerph-13-01096">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>S.Y.</given-names></name><name><surname>Surapureddi</surname><given-names>S.</given-names></name><name><surname>Coulter</surname><given-names>S.</given-names></name><name><surname>Ferguson</surname><given-names>S.S.</given-names></name><name><surname>Goldstein</surname><given-names>J.A.</given-names></name></person-group>
<article-title>Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver</article-title>
<source/>Mol. Pharmacol.
<year>2012</year>
<volume>82</volume>
<fpage>529</fpage>
<lpage>540</lpage>
<pub-id pub-id-type="doi">10.1124/mol.112.078386</pub-id>
<pub-id pub-id-type="pmid">22723340</pub-id></element-citation>
</ref>
<ref id="B18-ijerph-13-01096">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>D.</given-names></name><name><surname>Green</surname><given-names>B.</given-names></name><name><surname>Marrone</surname><given-names>A.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Kadlubar</surname><given-names>S.</given-names></name><name><surname>Lin</surname><given-names>D.</given-names></name><name><surname>Fuscoe</surname><given-names>J.</given-names></name><name><surname>Pogribny</surname><given-names>I.</given-names></name><name><surname>Ning</surname><given-names>B.</given-names></name></person-group>
<article-title>Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma</article-title>
<source/>Sci. Rep.
<year>2015</year>
<volume>5</volume>
<fpage>8534</fpage>
<pub-id pub-id-type="doi">10.1038/srep08534</pub-id>
<pub-id pub-id-type="pmid">25704921</pub-id></element-citation>
</ref>
<ref id="B19-ijerph-13-01096">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>D.</given-names></name><name><surname>Green</surname><given-names>B.</given-names></name><name><surname>Tolleson</surname><given-names>W.H.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Mei</surname><given-names>N.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>H.</given-names></name><name><surname>Pogribny</surname><given-names>I.</given-names></name><name><surname>Ning</surname><given-names>B.</given-names></name></person-group>
<article-title>MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells</article-title>
<source/>Biochem. Pharmacol.
<year>2015</year>
<volume>98</volume>
<fpage>215</fpage>
<lpage>123</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2015.08.094</pub-id>
<pub-id pub-id-type="pmid">26296572</pub-id></element-citation>
</ref>
<ref id="B20-ijerph-13-01096">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohri</surname><given-names>T.</given-names></name><name><surname>Nakajima</surname><given-names>M.</given-names></name><name><surname>Fukami</surname><given-names>T.</given-names></name><name><surname>Takamiya</surname><given-names>M.</given-names></name><name><surname>Aoki</surname><given-names>Y.</given-names></name><name><surname>Yokoi</surname><given-names>T.</given-names></name></person-group>
<article-title>Human CYP2E1 is regulated by miR-378</article-title>
<source/>Biochem. Pharmacol.
<year>2010</year>
<volume>79</volume>
<fpage>1045</fpage>
<lpage>1052</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2009.11.015</pub-id>
<pub-id pub-id-type="pmid">19945440</pub-id></element-citation>
</ref>
<ref id="B21-ijerph-13-01096">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shukla</surname><given-names>U.</given-names></name><name><surname>Tumma</surname><given-names>N.</given-names></name><name><surname>Gratsch</surname><given-names>T.</given-names></name><name><surname>Dombkowski</surname><given-names>A.</given-names></name><name><surname>Novak</surname><given-names>R.F.</given-names></name></person-group>
<article-title>Insights into insulin-mediated regulation of CYP2E1: miR-132/-212 targeting of CYP2E1 and role of phosphatidylinositol 3-kinase, Akt (protein kinase B), mammalian target of rapamycin signaling in regulating miR-132/-212 and miR-122/-181a expression in primary cultured rat hepatocytes</article-title>
<source/>Drug Metab. Dispos.
<year>2013</year>
<volume>41</volume>
<fpage>1769</fpage>
<lpage>1777</lpage>
<pub-id pub-id-type="pmid">23920219</pub-id></element-citation>
</ref>
<ref id="B22-ijerph-13-01096">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Gong</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Cianflone</surname><given-names>K.</given-names></name><name><surname>Tang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>D.W.</given-names></name></person-group>
<article-title>Let-7b inhibits human cancer phenotype by targeting cytochrome P450 epoxygenase 2J2</article-title>
<source/>PLoS ONE
<year>2012</year>
<volume>7</volume>
<elocation-id>e39197</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0039197</pub-id>
<pub-id pub-id-type="pmid">22761738</pub-id></element-citation>
</ref>
<ref id="B23-ijerph-13-01096">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y.Z.</given-names></name><name><surname>Gao</surname><given-names>W.</given-names></name><name><surname>Yu</surname><given-names>A.M.</given-names></name></person-group>
<article-title>MicroRNAs regulate CYP3A4 expression via direct and indirect targeting</article-title>
<source/>Drug Metab. Dispos.
<year>2009</year>
<volume>37</volume>
<fpage>2112</fpage>
<lpage>2117</lpage>
<pub-id pub-id-type="doi">10.1124/dmd.109.027680</pub-id>
<pub-id pub-id-type="pmid">19581388</pub-id></element-citation>
</ref>
<ref id="B24-ijerph-13-01096">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Peng</surname><given-names>X.</given-names></name><name><surname>Meng</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Qin</surname><given-names>S.</given-names></name><etal></etal></person-group>
<article-title>The effect of microRNAs in the regulation of human CYP3A4: A systematic study using a mathematical model</article-title>
<source/>Sci. Rep.
<year>2014</year>
<volume>4</volume>
<fpage>4283</fpage>
<pub-id pub-id-type="doi">10.1038/srep04283</pub-id>
<pub-id pub-id-type="pmid">24594634</pub-id></element-citation>
</ref>
<ref id="B25-ijerph-13-01096">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vuppalanchi</surname><given-names>R.</given-names></name><name><surname>Liang</surname><given-names>T.</given-names></name><name><surname>Goswami</surname><given-names>C.P.</given-names></name><name><surname>Nalamasu</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Jones</surname><given-names>D.</given-names></name><name><surname>Wei</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Sarasani</surname><given-names>V.</given-names></name><name><surname>Janga</surname><given-names>S.C.</given-names></name><etal></etal></person-group>
<article-title>Relationship between differential hepatic microRNA expression and decreased hepatic cytochrome P450 3A activity in cirrhosis</article-title>
<source/>PLoS ONE
<year>2013</year>
<volume>8</volume>
<elocation-id>e74471</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0074471</pub-id>
<pub-id pub-id-type="pmid">24058572</pub-id></element-citation>
</ref>
<ref id="B26-ijerph-13-01096">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shi</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Xing</surname><given-names>Q.</given-names></name><etal></etal></person-group>
<article-title>Hsa-miR-27a is involved in the regulation of CYP3A4 expression in human livers from Chinese Han population</article-title>
<source/>Pharmacogenomics
<year>2015</year>
<volume>16</volume>
<fpage>1379</fpage>
<lpage>1386</lpage>
<pub-id pub-id-type="doi">10.2217/pgs.15.82</pub-id>
<pub-id pub-id-type="pmid">26229046</pub-id></element-citation>
</ref>
<ref id="B27-ijerph-13-01096">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Song</surname><given-names>K.H.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Owsley</surname><given-names>E.</given-names></name><name><surname>Chiang</surname><given-names>J.Y.</given-names></name></person-group>
<article-title>A putative role of micro RNA in regulation of cholesterol 7alpha-hydroxylase expression in human hepatocytes</article-title>
<source/>J. Lipid Res.
<year>2010</year>
<volume>51</volume>
<fpage>2223</fpage>
<lpage>2233</lpage>
<pub-id pub-id-type="doi">10.1194/jlr.M004531</pub-id>
<pub-id pub-id-type="pmid">20351063</pub-id></element-citation>
</ref>
<ref id="B28-ijerph-13-01096">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>S.H.</given-names></name><name><surname>King</surname><given-names>A.N.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Simpson</surname><given-names>R.U.</given-names></name><name><surname>Christensen</surname><given-names>P.J.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Thomas</surname><given-names>D.G.</given-names></name><name><surname>Giordano</surname><given-names>T.J.</given-names></name><name><surname>Lin</surname><given-names>L.</given-names></name><etal></etal></person-group>
<article-title>CYP24A1 is an independent prognostic marker of survival in patients with lung adenocarcinoma</article-title>
<source/>Clin. Cancer Res.
<year>2011</year>
<volume>17</volume>
<fpage>817</fpage>
<lpage>826</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1789</pub-id>
<pub-id pub-id-type="pmid">21169243</pub-id></element-citation>
</ref>
<ref id="B29-ijerph-13-01096">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Komagata</surname><given-names>S.</given-names></name><name><surname>Nakajima</surname><given-names>M.</given-names></name><name><surname>Takagi</surname><given-names>S.</given-names></name><name><surname>Mohri</surname><given-names>T.</given-names></name><name><surname>Taniya</surname><given-names>T.</given-names></name><name><surname>Yokoi</surname><given-names>T.</given-names></name></person-group>
<article-title>Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b</article-title>
<source/>Mol. Pharmacol.
<year>2009</year>
<volume>76</volume>
<fpage>702</fpage>
<lpage>709</lpage>
<pub-id pub-id-type="doi">10.1124/mol.109.056986</pub-id>
<pub-id pub-id-type="pmid">19570947</pub-id></element-citation>
</ref>
<ref id="B30-ijerph-13-01096">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mohri</surname><given-names>T.</given-names></name><name><surname>Nakajima</surname><given-names>M.</given-names></name><name><surname>Takagi</surname><given-names>S.</given-names></name><name><surname>Komagata</surname><given-names>S.</given-names></name><name><surname>Yokoi</surname><given-names>T.</given-names></name></person-group>
<article-title>MicroRNA regulates human vitamin D receptor</article-title>
<source/>Int. J. Cancer
<year>2009</year>
<volume>125</volume>
<fpage>1328</fpage>
<lpage>1333</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.24459</pub-id>
<pub-id pub-id-type="pmid">19437538</pub-id></element-citation>
</ref>
<ref id="B31-ijerph-13-01096">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Choi</surname><given-names>Y.H.</given-names></name><name><surname>Yu</surname><given-names>A.M.</given-names></name></person-group>
<article-title>ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development</article-title>
<source/>Curr. Pharm. Des.
<year>2014</year>
<volume>20</volume>
<fpage>793</fpage>
<lpage>807</lpage>
<pub-id pub-id-type="doi">10.2174/138161282005140214165212</pub-id>
<pub-id pub-id-type="pmid">23688078</pub-id></element-citation>
</ref>
<ref id="B32-ijerph-13-01096">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pan</surname><given-names>S.T.</given-names></name><name><surname>Li</surname><given-names>Z.L.</given-names></name><name><surname>He</surname><given-names>Z.X.</given-names></name><name><surname>Qiu</surname><given-names>J.X.</given-names></name><name><surname>Zhou</surname><given-names>S.F.</given-names></name></person-group>
<article-title>Molecular mechanisms for tumour resistance to chemotherapy</article-title>
<source/>Clin. Exp. Pharmacol. Physiol.
<year>2016</year>
<volume>43</volume>
<fpage>723</fpage>
<lpage>737</lpage>
<pub-id pub-id-type="doi">10.1111/1440-1681.12581</pub-id>
<pub-id pub-id-type="pmid">27097837</pub-id></element-citation>
</ref>
<ref id="B33-ijerph-13-01096">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boyerinas</surname><given-names>B.</given-names></name><name><surname>Park</surname><given-names>S.M.</given-names></name><name><surname>Murmann</surname><given-names>A.E.</given-names></name><name><surname>Gwin</surname><given-names>K.</given-names></name><name><surname>Montag</surname><given-names>A.G.</given-names></name><name><surname>Zillhardt</surname><given-names>M.</given-names></name><name><surname>Hua</surname><given-names>Y.J.</given-names></name><name><surname>Lengyel</surname><given-names>E.</given-names></name><name><surname>Peter</surname><given-names>M.E.</given-names></name></person-group>
<article-title>Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1</article-title>
<source/>Int. J. Cancer
<year>2012</year>
<volume>130</volume>
<fpage>1787</fpage>
<lpage>1797</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.26190</pub-id>
<pub-id pub-id-type="pmid">21618519</pub-id></element-citation>
</ref>
<ref id="B34-ijerph-13-01096">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Evans</surname><given-names>B.R.</given-names></name><name><surname>Medina</surname><given-names>D.J.</given-names></name><name><surname>Liu</surname><given-names>C.G.</given-names></name><name><surname>Yang</surname><given-names>J.M.</given-names></name></person-group>
<article-title>Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells</article-title>
<source/>Biochem. Pharmacol.
<year>2008</year>
<volume>76</volume>
<fpage>582</fpage>
<lpage>588</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2008.06.007</pub-id>
<pub-id pub-id-type="pmid">18619946</pub-id></element-citation>
</ref>
<ref id="B35-ijerph-13-01096">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Hu</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>J.</given-names></name><name><surname>Xiao</surname><given-names>L.</given-names></name><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name></person-group>
<article-title>MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells</article-title>
<source/>Gynecol. Oncol.
<year>2010</year>
<volume>119</volume>
<fpage>125</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1016/j.ygyno.2010.06.004</pub-id>
<pub-id pub-id-type="pmid">20624637</pub-id></element-citation>
</ref>
<ref id="B36-ijerph-13-01096">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bitarte</surname><given-names>N.</given-names></name><name><surname>Bandres</surname><given-names>E.</given-names></name><name><surname>Boni</surname><given-names>V.</given-names></name><name><surname>Zarate</surname><given-names>R.</given-names></name><name><surname>Rodriguez</surname><given-names>J.</given-names></name><name><surname>Gonzalez-Huarriz</surname><given-names>M.</given-names></name><name><surname>Lopez</surname><given-names>I.</given-names></name><name><surname>Javier Sola</surname><given-names>J.</given-names></name><name><surname>Alonso</surname><given-names>M.M.</given-names></name><name><surname>Fortes</surname><given-names>P.</given-names></name><etal></etal></person-group>
<article-title>MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells</article-title>
<source/>Stem Cell
<year>2011</year>
<volume>29</volume>
<fpage>1661</fpage>
<lpage>1671</lpage>
<pub-id pub-id-type="doi">10.1002/stem.741</pub-id>
<pub-id pub-id-type="pmid">21948564</pub-id></element-citation>
</ref>
<ref id="B37-ijerph-13-01096">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Hazari</surname><given-names>S.</given-names></name><name><surname>Mehra</surname><given-names>S.</given-names></name><name><surname>Kaushal</surname><given-names>D.</given-names></name><name><surname>Moroz</surname><given-names>K.</given-names></name><name><surname>Dash</surname><given-names>S.</given-names></name></person-group>
<article-title>Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298</article-title>
<source/>Am. J. Pathol.
<year>2012</year>
<volume>180</volume>
<fpage>2490</fpage>
<lpage>2503</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajpath.2012.02.024</pub-id>
<pub-id pub-id-type="pmid">22521303</pub-id></element-citation>
</ref>
<ref id="B38-ijerph-13-01096">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yang</surname><given-names>T.</given-names></name><name><surname>Zheng</surname><given-names>Z.M.</given-names></name><name><surname>Li</surname><given-names>X.N.</given-names></name><name><surname>Li</surname><given-names>Z.F.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Geng</surname><given-names>Y.F.</given-names></name><name><surname>Bai</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>X.B.</given-names></name></person-group>
<article-title>MiR-223 modulates multidrug resistance via downregulation of ABCB1 in hepatocellular carcinoma cells</article-title>
<source/>Exp. Biol. Med.
<year>2013</year>
<volume>238</volume>
<fpage>1024</fpage>
<lpage>1032</lpage>
<pub-id pub-id-type="doi">10.1177/1535370213497321</pub-id>
<pub-id pub-id-type="pmid">23925649</pub-id></element-citation>
</ref>
<ref id="B39-ijerph-13-01096">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shang</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Feng</surname><given-names>B.</given-names></name><name><surname>Ren</surname><given-names>G.</given-names></name><name><surname>Li</surname><given-names>K.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><etal></etal></person-group>
<article-title>MiR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1</article-title>
<source/>Oncogene
<year>2014</year>
<volume>33</volume>
<fpage>3267</fpage>
<lpage>3276</lpage>
<pub-id pub-id-type="doi">10.1038/onc.2013.297</pub-id>
<pub-id pub-id-type="pmid">23893241</pub-id></element-citation>
</ref>
<ref id="B40-ijerph-13-01096">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ikemura</surname><given-names>K.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name><name><surname>Miyazaki</surname><given-names>S.</given-names></name><name><surname>Mizutani</surname><given-names>H.</given-names></name><name><surname>Iwamoto</surname><given-names>T.</given-names></name><name><surname>Okuda</surname><given-names>M.</given-names></name></person-group>
<article-title>MicroRNA-145 post-transcriptionally regulates the expression and function of P-glycoprotein in intestinal epithelial cells</article-title>
<source/>Mol. Pharmacol.
<year>2013</year>
<volume>83</volume>
<fpage>399</fpage>
<lpage>405</lpage>
<pub-id pub-id-type="doi">10.1124/mol.112.081844</pub-id>
<pub-id pub-id-type="pmid">23166305</pub-id></element-citation>
</ref>
<ref id="B41-ijerph-13-01096">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dong</surname><given-names>Z.</given-names></name><name><surname>Zhong</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Gong</surname><given-names>Z.</given-names></name></person-group>
<article-title>MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9</article-title>
<source/>Cancer Lett.
<year>2014</year>
<volume>343</volume>
<fpage>249</fpage>
<lpage>257</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2013.09.034</pub-id>
<pub-id pub-id-type="pmid">24099915</pub-id></element-citation>
</ref>
<ref id="B42-ijerph-13-01096">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y.K.</given-names></name><name><surname>Wang</surname><given-names>Y.J.</given-names></name><name><surname>Gupta</surname><given-names>P.</given-names></name><name><surname>Chen</surname><given-names>Z.S.</given-names></name></person-group>
<article-title>Multidrug Resistance Proteins (MRPs) and Cancer Therapy</article-title>
<source/>AAPS J.
<year>2015</year>
<volume>17</volume>
<fpage>802</fpage>
<lpage>812</lpage>
<pub-id pub-id-type="doi">10.1208/s12248-015-9757-1</pub-id>
<pub-id pub-id-type="pmid">25840885</pub-id></element-citation>
</ref>
<ref id="B43-ijerph-13-01096">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liang</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>H.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>K.</given-names></name><name><surname>Wagar</surname><given-names>N.</given-names></name><name><surname>Yoon</surname><given-names>Y.</given-names></name><name><surname>Cho</surname><given-names>H.T.</given-names></name><name><surname>Scala</surname><given-names>S.</given-names></name><etal></etal></person-group>
<article-title>Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1</article-title>
<source/>Biochem. Pharmacol.
<year>2010</year>
<volume>79</volume>
<fpage>817</fpage>
<lpage>824</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2009.10.017</pub-id>
<pub-id pub-id-type="pmid">19883630</pub-id></element-citation>
</ref>
<ref id="B44-ijerph-13-01096">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Bai</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>F.</given-names></name><name><surname>Guo</surname><given-names>Y.</given-names></name></person-group>
<article-title>Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis</article-title>
<source/>Eur. J. Cancer
<year>2010</year>
<volume>46</volume>
<fpage>1692</fpage>
<lpage>1702</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejca.2010.02.043</pub-id>
<pub-id pub-id-type="pmid">20371173</pub-id></element-citation>
</ref>
<ref id="B45-ijerph-13-01096">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Xia</surname><given-names>F.</given-names></name><name><surname>Ma</surname><given-names>L.</given-names></name><name><surname>Shan</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Cui</surname><given-names>Y.</given-names></name><name><surname>Bian</surname><given-names>X.</given-names></name><name><surname>Bie</surname><given-names>P.</given-names></name><etal></etal></person-group>
<article-title>MicroRNA-122 sensitizes HCC cancer cells to adriamycin and vincristine through modulating expression of MDR and inducing cell cycle arrest</article-title>
<source/>Cancer Lett.
<year>2011</year>
<volume>310</volume>
<fpage>160</fpage>
<lpage>169</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2011.06.027</pub-id>
<pub-id pub-id-type="pmid">21802841</pub-id></element-citation>
</ref>
<ref id="B46-ijerph-13-01096">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y.Z.</given-names></name><name><surname>Zhou</surname><given-names>A.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Yu</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Small nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1</article-title>
<source/>Drug Metab. Dispos.
<year>2013</year>
<volume>41</volume>
<fpage>1744</fpage>
<lpage>1751</lpage>
<pub-id pub-id-type="doi">10.1124/dmd.113.052092</pub-id>
<pub-id pub-id-type="pmid">23686318</pub-id></element-citation>
</ref>
<ref id="B47-ijerph-13-01096">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name></person-group>
<article-title>MiR-7 modulates chemoresistance of small cell lung cancer by repressing MRP1/ABCC1</article-title>
<source/>Int. J. Exp. Pathol.
<year>2015</year>
<volume>96</volume>
<fpage>240</fpage>
<lpage>247</lpage>
<pub-id pub-id-type="doi">10.1111/iep.12131</pub-id>
<pub-id pub-id-type="pmid">26108539</pub-id></element-citation>
</ref>
<ref id="B48-ijerph-13-01096">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haenisch</surname><given-names>S.</given-names></name><name><surname>Laechelt</surname><given-names>S.</given-names></name><name><surname>Bruckmueller</surname><given-names>H.</given-names></name><name><surname>Werk</surname><given-names>A.</given-names></name><name><surname>Noack</surname><given-names>A.</given-names></name><name><surname>Bruhn</surname><given-names>O.</given-names></name><name><surname>Remmler</surname><given-names>C.</given-names></name><name><surname>Cascorbi</surname><given-names>I.</given-names></name></person-group>
<article-title>Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379</article-title>
<source/>Mol. Pharmacol.
<year>2011</year>
<volume>80</volume>
<fpage>314</fpage>
<lpage>320</lpage>
<pub-id pub-id-type="doi">10.1124/mol.110.070714</pub-id>
<pub-id pub-id-type="pmid">21540293</pub-id></element-citation>
</ref>
<ref id="B49-ijerph-13-01096">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Werk</surname><given-names>A.N.</given-names></name><name><surname>Bruckmueller</surname><given-names>H.</given-names></name><name><surname>Haenisch</surname><given-names>S.</given-names></name><name><surname>Cascorbi</surname><given-names>I.</given-names></name></person-group>
<article-title>Genetic variants may play an important role in mRNA-miRNA interaction: Evidence for haplotype-dependent downregulation of ABCC2 (MRP2) by miRNA-379</article-title>
<source/>Pharmacogenet. Genom.
<year>2014</year>
<volume>24</volume>
<fpage>283</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0000000000000046</pub-id>
<pub-id pub-id-type="pmid">24743544</pub-id></element-citation>
</ref>
<ref id="B50-ijerph-13-01096">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>K.</given-names></name><name><surname>Liang</surname><given-names>X.</given-names></name><name><surname>Shen</surname><given-names>K.</given-names></name><name><surname>Cui</surname><given-names>D.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Fan</surname><given-names>Z.</given-names></name><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Ni</surname><given-names>L.</given-names></name><etal></etal></person-group>
<article-title>MiR-297 modulates multidrug resistance in human colorectal carcinoma by down-regulating MRP-2</article-title>
<source/>Biochem. J.
<year>2012</year>
<volume>446</volume>
<fpage>291</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20120386</pub-id>
<pub-id pub-id-type="pmid">22676135</pub-id></element-citation>
</ref>
<ref id="B51-ijerph-13-01096">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhan</surname><given-names>M.</given-names></name><name><surname>Qu</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>G.</given-names></name><name><surname>Zhou</surname><given-names>H.</given-names></name></person-group>
<article-title>Let-7c sensitizes acquired cisplatin-resistant A549 cells by targeting ABCC2 and Bcl-XL</article-title>
<source/>Die Pharm.
<year>2013</year>
<volume>68</volume>
<fpage>955</fpage>
<lpage>961</lpage>
</element-citation>
</ref>
<ref id="B52-ijerph-13-01096">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borel</surname><given-names>F.</given-names></name><name><surname>Han</surname><given-names>R.</given-names></name><name><surname>Visser</surname><given-names>A.</given-names></name><name><surname>Petry</surname><given-names>H.</given-names></name><name><surname>van Deventer</surname><given-names>S.J.</given-names></name><name><surname>Jansen</surname><given-names>P.L.</given-names></name><name><surname>Konstantinova</surname><given-names>P.</given-names></name><collab>Réseau Centre de Ressources Biologiques Foie (French Liver Biobanks Network), France</collab></person-group>
<article-title>Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs</article-title>
<source/>Hepatology
<year>2012</year>
<volume>55</volume>
<fpage>821</fpage>
<lpage>832</lpage>
<pub-id pub-id-type="doi">10.1002/hep.24682</pub-id>
<pub-id pub-id-type="pmid">21932399</pub-id></element-citation>
</ref>
<ref id="B53-ijerph-13-01096">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Markova</surname><given-names>S.M.</given-names></name><name><surname>Kroetz</surname><given-names>D.L.</given-names></name></person-group>
<article-title>ABCC4 is regulated by microRNA-124a and microRNA-506</article-title>
<source/>Biochem. Pharmacol.
<year>2014</year>
<volume>87</volume>
<fpage>515</fpage>
<lpage>522</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2013.10.017</pub-id>
<pub-id pub-id-type="pmid">24184504</pub-id></element-citation>
</ref>
<ref id="B54-ijerph-13-01096">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>F.</given-names></name><name><surname>Jiao</surname><given-names>Y.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Tang</surname><given-names>W.</given-names></name><name><surname>Yao</surname><given-names>H.</given-names></name><name><surname>Gong</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Su</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><etal></etal></person-group>
<article-title>Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5</article-title>
<source/>Clin. Cancer Res.
<year>2011</year>
<volume>17</volume>
<fpage>7105</fpage>
<lpage>7115</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-0071</pub-id>
<pub-id pub-id-type="pmid">21953503</pub-id></element-citation>
</ref>
<ref id="B55-ijerph-13-01096">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Robey</surname><given-names>R.W.</given-names></name><name><surname>Polgar</surname><given-names>O.</given-names></name><name><surname>Deeken</surname><given-names>J.</given-names></name><name><surname>To</surname><given-names>K.W.</given-names></name><name><surname>Bates</surname><given-names>S.E.</given-names></name></person-group>
<article-title>ABCG2: Determining its relevance in clinical drug resistance</article-title>
<source/>Cancer Metast. Rev.
<year>2007</year>
<volume>26</volume>
<fpage>39</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1007/s10555-007-9042-6</pub-id>
<pub-id pub-id-type="pmid">17323127</pub-id></element-citation>
</ref>
<ref id="B56-ijerph-13-01096">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>An</surname><given-names>Y.</given-names></name><name><surname>Ongkeko</surname><given-names>W.M.</given-names></name></person-group>
<article-title>ABCG2: The key to chemoresistance in cancer stem cells?</article-title>
<source/>Expert Opin. Drug Metab. Toxicol.
<year>2009</year>
<volume>5</volume>
<fpage>1529</fpage>
<lpage>1542</lpage>
<pub-id pub-id-type="doi">10.1517/17425250903228834</pub-id>
<pub-id pub-id-type="pmid">19708828</pub-id></element-citation>
</ref>
<ref id="B57-ijerph-13-01096">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pan</surname><given-names>Y.Z.</given-names></name><name><surname>Morris</surname><given-names>M.E.</given-names></name><name><surname>Yu</surname><given-names>A.M.</given-names></name></person-group>
<article-title>MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells</article-title>
<source/>Mol. Pharmacol.
<year>2009</year>
<volume>75</volume>
<fpage>1374</fpage>
<lpage>1379</lpage>
<pub-id pub-id-type="doi">10.1124/mol.108.054163</pub-id>
<pub-id pub-id-type="pmid">19270061</pub-id></element-citation>
</ref>
<ref id="B58-ijerph-13-01096">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>W.Q.</given-names></name><name><surname>Li</surname><given-names>Y.M.</given-names></name><name><surname>Tao</surname><given-names>B.B.</given-names></name><name><surname>Lu</surname><given-names>Y.C.</given-names></name><name><surname>Hu</surname><given-names>G.H.</given-names></name><name><surname>Liu</surname><given-names>H.M.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>H.Y.</given-names></name></person-group>
<article-title>Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance</article-title>
<source/>Med. Sci. Monit.
<year>2010</year>
<volume>16</volume>
<fpage>HY27</fpage>
<lpage>HY30</lpage>
<pub-id pub-id-type="pmid">20885358</pub-id></element-citation>
</ref>
<ref id="B59-ijerph-13-01096">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>X.T.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Tong</surname><given-names>J.L.</given-names></name><name><surname>Zhu</surname><given-names>M.M.</given-names></name><name><surname>Nie</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Xiao</surname><given-names>S.D.</given-names></name><name><surname>Ran</surname><given-names>Z.H.</given-names></name></person-group>
<article-title>MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer</article-title>
<source/>Br. J. Cancer
<year>2012</year>
<volume>106</volume>
<fpage>1320</fpage>
<lpage>1330</lpage>
<pub-id pub-id-type="doi">10.1038/bjc.2012.88</pub-id>
<pub-id pub-id-type="pmid">22453125</pub-id></element-citation>
</ref>
<ref id="B60-ijerph-13-01096">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Pan</surname><given-names>Y.Z.</given-names></name><name><surname>Seigel</surname><given-names>G.M.</given-names></name><name><surname>Hu</surname><given-names>Z.H.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells</article-title>
<source/>Biochem. Pharmacol.
<year>2011</year>
<volume>81</volume>
<fpage>783</fpage>
<lpage>792</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2010.12.018</pub-id>
<pub-id pub-id-type="pmid">21219875</pub-id></element-citation>
</ref>
<ref id="B61-ijerph-13-01096">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Turrini</surname><given-names>E.</given-names></name><name><surname>Haenisch</surname><given-names>S.</given-names></name><name><surname>Laechelt</surname><given-names>S.</given-names></name><name><surname>Diewock</surname><given-names>T.</given-names></name><name><surname>Bruhn</surname><given-names>O.</given-names></name><name><surname>Cascorbi</surname><given-names>I.</given-names></name></person-group>
<article-title>MicroRNA profiling in K-562 cells under imatinib treatment: Influence of miR-212 and miR-328 on ABCG2 expression</article-title>
<source/>Pharmacogenet. Genom.
<year>2012</year>
<volume>22</volume>
<fpage>198</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0b013e328350012b</pub-id>
<pub-id pub-id-type="pmid">22241070</pub-id></element-citation>
</ref>
<ref id="B62-ijerph-13-01096">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liao</surname><given-names>R.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Lou</surname><given-names>G.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name></person-group>
<article-title>MicroRNAs play a role in the development of human hematopoietic stem cells</article-title>
<source/>J. Cell. Biochem.
<year>2008</year>
<volume>104</volume>
<fpage>805</fpage>
<lpage>817</lpage>
<pub-id pub-id-type="doi">10.1002/jcb.21668</pub-id>
<pub-id pub-id-type="pmid">18189265</pub-id></element-citation>
</ref>
<ref id="B63-ijerph-13-01096">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Xue</surname><given-names>X.</given-names></name><name><surname>Wei</surname><given-names>J.</given-names></name><name><surname>An</surname><given-names>Y.</given-names></name><name><surname>Yao</surname><given-names>J.</given-names></name><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Wu</surname><given-names>J.</given-names></name><name><surname>Dai</surname><given-names>C.</given-names></name><name><surname>Qian</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><etal></etal></person-group>
<article-title>Hsa-miR-520h downregulates ABCG2 in pancreatic cancer cells to inhibit migration, invasion, and side populations</article-title>
<source/>Br. J. Cancer
<year>2010</year>
<volume>103</volume>
<fpage>567</fpage>
<lpage>574</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjc.6605724</pub-id>
<pub-id pub-id-type="pmid">20628378</pub-id></element-citation>
</ref>
<ref id="B64-ijerph-13-01096">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jiao</surname><given-names>X.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>M.</given-names></name><name><surname>Bai</surname><given-names>X.</given-names></name><name><surname>He</surname><given-names>M.</given-names></name><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>M.</given-names></name><etal></etal></person-group>
<article-title>MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2)</article-title>
<source/>Breast Cancer Res. Treat.
<year>2013</year>
<volume>139</volume>
<fpage>717</fpage>
<lpage>730</lpage>
<pub-id pub-id-type="doi">10.1007/s10549-013-2607-x</pub-id>
<pub-id pub-id-type="pmid">23780685</pub-id></element-citation>
</ref>
<ref id="B65-ijerph-13-01096">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ma</surname><given-names>M.T.</given-names></name><name><surname>He</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Jiao</surname><given-names>X.Y.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Bai</surname><given-names>X.F.</given-names></name><name><surname>Yu</surname><given-names>Z.J.</given-names></name><name><surname>Wu</surname><given-names>H.Z.</given-names></name><name><surname>Sun</surname><given-names>M.L.</given-names></name><name><surname>Song</surname><given-names>Z.G.</given-names></name><etal></etal></person-group>
<article-title>MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2)</article-title>
<source/>Cancer Lett.
<year>2013</year>
<volume>339</volume>
<fpage>107</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="doi">10.1016/j.canlet.2013.07.016</pub-id>
<pub-id pub-id-type="pmid">23879965</pub-id></element-citation>
</ref>
<ref id="B66-ijerph-13-01096">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baudry</surname><given-names>A.</given-names></name><name><surname>Mouillet-Richard</surname><given-names>S.</given-names></name><name><surname>Schneider</surname><given-names>B.</given-names></name><name><surname>Launay</surname><given-names>J.M.</given-names></name><name><surname>Kellermann</surname><given-names>O.</given-names></name></person-group>
<article-title>MiR-16 targets the serotonin transporter: A new facet for adaptive responses to antidepressants</article-title>
<source/>Science
<year>2010</year>
<volume>329</volume>
<fpage>1537</fpage>
<lpage>1541</lpage>
<pub-id pub-id-type="doi">10.1126/science.1193692</pub-id>
<pub-id pub-id-type="pmid">20847275</pub-id></element-citation>
</ref>
<ref id="B67-ijerph-13-01096">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tamarapu Parthasarathy</surname><given-names>P.</given-names></name><name><surname>Galam</surname><given-names>L.</given-names></name><name><surname>Huynh</surname><given-names>B.</given-names></name><name><surname>Yunus</surname><given-names>A.</given-names></name><name><surname>Abuelenen</surname><given-names>T.</given-names></name><name><surname>Castillo</surname><given-names>A.</given-names></name><name><surname>Kollongod Ramanathan</surname><given-names>G.</given-names></name><name><surname>Cox</surname><given-names>R.</given-names><suffix>Jr.</suffix></name><name><surname>Kolliputi</surname><given-names>N.</given-names></name></person-group>
<article-title>MicroRNA 16 modulates epithelial sodium channel in human alveolar epithelial cells</article-title>
<source/>Biochem. Biophys. Res. Commun.
<year>2012</year>
<volume>426</volume>
<fpage>203</fpage>
<lpage>208</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2012.08.063</pub-id>
<pub-id pub-id-type="pmid">22940131</pub-id></element-citation>
</ref>
<ref id="B68-ijerph-13-01096">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Moya</surname><given-names>P.R.</given-names></name><name><surname>Wendland</surname><given-names>J.R.</given-names></name><name><surname>Salemme</surname><given-names>J.</given-names></name><name><surname>Fried</surname><given-names>R.L.</given-names></name><name><surname>Murphy</surname><given-names>D.L.</given-names></name></person-group>
<article-title>MiR-15a and miR-16 regulate serotonin transporter expression in human placental and rat brain raphe cells</article-title>
<source/>Int. J. Neuropsychopharmacol.
<year>2013</year>
<volume>16</volume>
<fpage>621</fpage>
<lpage>629</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145712000454</pub-id>
<pub-id pub-id-type="pmid">22564678</pub-id></element-citation>
</ref>
<ref id="B69-ijerph-13-01096">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miko</surname><given-names>E.</given-names></name><name><surname>Margitai</surname><given-names>Z.</given-names></name><name><surname>Czimmerer</surname><given-names>Z.</given-names></name><name><surname>Varkonyi</surname><given-names>I.</given-names></name><name><surname>Dezso</surname><given-names>B.</given-names></name><name><surname>Lanyi</surname><given-names>A.</given-names></name><name><surname>Bacso</surname><given-names>Z.</given-names></name><name><surname>Scholtz</surname><given-names>B.</given-names></name></person-group>
<article-title>MiR-126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5</article-title>
<source/>FEBS Lett.
<year>2011</year>
<volume>585</volume>
<fpage>1191</fpage>
<lpage>1196</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2011.03.039</pub-id>
<pub-id pub-id-type="pmid">21439283</pub-id></element-citation>
</ref>
<ref id="B70-ijerph-13-01096">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Drayton</surname><given-names>R.M.</given-names></name><name><surname>Dudziec</surname><given-names>E.</given-names></name><name><surname>Peter</surname><given-names>S.</given-names></name><name><surname>Bertz</surname><given-names>S.</given-names></name><name><surname>Hartmann</surname><given-names>A.</given-names></name><name><surname>Bryant</surname><given-names>H.E.</given-names></name><name><surname>Catto</surname><given-names>J.W.</given-names></name></person-group>
<article-title>Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11</article-title>
<source/>Clin. Cancer Res.
<year>2014</year>
<volume>20</volume>
<fpage>1990</fpage>
<lpage>2000</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-13-2805</pub-id>
<pub-id pub-id-type="pmid">24516043</pub-id></element-citation>
</ref>
<ref id="B71-ijerph-13-01096">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gillen</surname><given-names>A.E.</given-names></name><name><surname>Gosalia</surname><given-names>N.</given-names></name><name><surname>Leir</surname><given-names>S.H.</given-names></name><name><surname>Harris</surname><given-names>A.</given-names></name></person-group>
<article-title>MicroRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene</article-title>
<source/>Biochem. J.
<year>2011</year>
<volume>438</volume>
<fpage>25</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1042/BJ20110672</pub-id>
<pub-id pub-id-type="pmid">21689072</pub-id></element-citation>
</ref>
<ref id="B72-ijerph-13-01096">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dalmasso</surname><given-names>G.</given-names></name><name><surname>Nguyen</surname><given-names>H.T.</given-names></name><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Laroui</surname><given-names>H.</given-names></name><name><surname>Charania</surname><given-names>M.A.</given-names></name><name><surname>Obertone</surname><given-names>T.S.</given-names></name><name><surname>Sitaraman</surname><given-names>S.V.</given-names></name><name><surname>Merlin</surname><given-names>D.</given-names></name></person-group>
<article-title>MicroRNA-92b regulates expression of the oligopeptide transporter PepT1 in intestinal epithelial cells</article-title>
<source/>Am. J. Physiol. Gastrointest. Liver Physiol.
<year>2011</year>
<volume>300</volume>
<fpage>G52</fpage>
<lpage>G59</lpage>
<pub-id pub-id-type="doi">10.1152/ajpgi.00394.2010</pub-id>
<pub-id pub-id-type="pmid">21030610</pub-id></element-citation>
</ref>
<ref id="B73-ijerph-13-01096">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>K.K.</given-names></name><name><surname>Pang</surname><given-names>J.C.</given-names></name><name><surname>Ching</surname><given-names>A.K.</given-names></name><name><surname>Wong</surname><given-names>C.K.</given-names></name><name><surname>Kong</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Ng</surname><given-names>H.K.</given-names></name></person-group>
<article-title>MiR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1</article-title>
<source/>Hum. Pathol.
<year>2009</year>
<volume>40</volume>
<fpage>1234</fpage>
<lpage>1243</lpage>
<pub-id pub-id-type="doi">10.1016/j.humpath.2009.02.003</pub-id>
<pub-id pub-id-type="pmid">19427019</pub-id></element-citation>
</ref>
<ref id="B74-ijerph-13-01096">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pullen</surname><given-names>T.J.</given-names></name><name><surname>da Silva Xavier</surname><given-names>G.</given-names></name><name><surname>Kelsey</surname><given-names>G.</given-names></name><name><surname>Rutter</surname><given-names>G.A.</given-names></name></person-group>
<article-title>MiR-29a and miR-29b contribute to pancreatic beta-cell-specific silencing of monocarboxylate transporter 1 (Mct1)</article-title>
<source/>Mol. Cell. Biol.
<year>2011</year>
<volume>31</volume>
<fpage>3182</fpage>
<lpage>3194</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.01433-10</pub-id>
<pub-id pub-id-type="pmid">21646425</pub-id></element-citation>
</ref>
<ref id="B75-ijerph-13-01096">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kamiyama</surname><given-names>Y.</given-names></name><name><surname>Matsubara</surname><given-names>T.</given-names></name><name><surname>Yoshinari</surname><given-names>K.</given-names></name><name><surname>Nagata</surname><given-names>K.</given-names></name><name><surname>Kamimura</surname><given-names>H.</given-names></name><name><surname>Yamazoe</surname><given-names>Y.</given-names></name></person-group>
<article-title>Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA</article-title>
<source/>Drug Metab. Pharm.
<year>2007</year>
<volume>22</volume>
<fpage>287</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="doi">10.2133/dmpk.22.287</pub-id>
</element-citation>
</ref>
<ref id="B76-ijerph-13-01096">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takagi</surname><given-names>S.</given-names></name><name><surname>Nakajima</surname><given-names>M.</given-names></name><name><surname>Kida</surname><given-names>K.</given-names></name><name><surname>Yamaura</surname><given-names>Y.</given-names></name><name><surname>Fukami</surname><given-names>T.</given-names></name><name><surname>Yokoi</surname><given-names>T.</given-names></name></person-group>
<article-title>MicroRNAs regulate human hepatocyte nuclear factor 4alpha, modulating the expression of metabolic enzymes and cell cycle</article-title>
<source/>J. Biol. Chem.
<year>2010</year>
<volume>285</volume>
<fpage>4415</fpage>
<lpage>4422</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M109.085431</pub-id>
<pub-id pub-id-type="pmid">20018894</pub-id></element-citation>
</ref>
<ref id="B77-ijerph-13-01096">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hatziapostolou</surname><given-names>M.</given-names></name><name><surname>Polytarchou</surname><given-names>C.</given-names></name><name><surname>Aggelidou</surname><given-names>E.</given-names></name><name><surname>Drakaki</surname><given-names>A.</given-names></name><name><surname>Poultsides</surname><given-names>G.A.</given-names></name><name><surname>Jaeger</surname><given-names>S.A.</given-names></name><name><surname>Ogata</surname><given-names>H.</given-names></name><name><surname>Karin</surname><given-names>M.</given-names></name><name><surname>Struhl</surname><given-names>K.</given-names></name><name><surname>Hadzopoulou-Cladaras</surname><given-names>M.</given-names></name><etal></etal></person-group>
<article-title>An HNF4alpha-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis</article-title>
<source/>Cell
<year>2011</year>
<volume>147</volume>
<fpage>1233</fpage>
<lpage>1247</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2011.10.043</pub-id>
<pub-id pub-id-type="pmid">22153071</pub-id></element-citation>
</ref>
<ref id="B78-ijerph-13-01096">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ramamoorthy</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Gaedigk</surname><given-names>A.</given-names></name><name><surname>Bradford</surname><given-names>L.D.</given-names></name><name><surname>Benson</surname><given-names>E.A.</given-names></name><name><surname>Flockhart</surname><given-names>D.A.</given-names></name><name><surname>Skaar</surname><given-names>T.C.</given-names></name></person-group>
<article-title>In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4alpha expression</article-title>
<source/>Drug Metab. Dispos.
<year>2012</year>
<volume>40</volume>
<fpage>726</fpage>
<lpage>733</lpage>
<pub-id pub-id-type="doi">10.1124/dmd.111.040329</pub-id>
<pub-id pub-id-type="pmid">22232426</pub-id></element-citation>
</ref>
<ref id="B79-ijerph-13-01096">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Burke</surname><given-names>P.A.</given-names></name></person-group>
<article-title>The role of microRNAs in hepatocyte nuclear factor-4alpha expression and transactivation</article-title>
<source/>Biochim. Biophys. Acta
<year>2013</year>
<volume>1829</volume>
<fpage>436</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbagrm.2012.12.009</pub-id>
<pub-id pub-id-type="pmid">23298640</pub-id></element-citation>
</ref>
<ref id="B80-ijerph-13-01096">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takagi</surname><given-names>S.</given-names></name><name><surname>Nakajima</surname><given-names>M.</given-names></name><name><surname>Mohri</surname><given-names>T.</given-names></name><name><surname>Yokoi</surname><given-names>T.</given-names></name></person-group>
<article-title>Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4</article-title>
<source/>J. Biol. Chem.
<year>2008</year>
<volume>283</volume>
<fpage>9674</fpage>
<lpage>9680</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M709382200</pub-id>
<pub-id pub-id-type="pmid">18268015</pub-id></element-citation>
</ref>
<ref id="B81-ijerph-13-01096">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wei</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Qin</surname><given-names>S.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><etal></etal></person-group>
<article-title>No correlation of hsa-miR-148a with expression of PXR or CYP3A4 in human livers from Chinese Han population</article-title>
<source/>PLoS ONE
<year>2013</year>
<volume>8</volume>
<elocation-id>e59141</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0059141</pub-id>
<pub-id pub-id-type="pmid">23527115</pub-id></element-citation>
</ref>
<ref id="B82-ijerph-13-01096">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Schuetz</surname><given-names>E.G.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Thummel</surname><given-names>K.E.</given-names></name></person-group>
<article-title>Interplay between vitamin D and the drug metabolizing enzyme CYP3A4</article-title>
<source/>J. Steroid Biochem. Mol. Biol.
<year>2013</year>
<volume>136</volume>
<fpage>54</fpage>
<lpage>58</lpage>
<pub-id pub-id-type="doi">10.1016/j.jsbmb.2012.09.012</pub-id>
<pub-id pub-id-type="pmid">22985909</pub-id></element-citation>
</ref>
<ref id="B83-ijerph-13-01096">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keenan</surname><given-names>C.R.</given-names></name><name><surname>Lew</surname><given-names>M.J.</given-names></name><name><surname>Stewart</surname><given-names>A.G.</given-names></name></person-group>
<article-title>Biased signalling from the glucocorticoid receptor: Renewed opportunity for tailoring glucocorticoid activity</article-title>
<source/>Biochem. Pharmacol.
<year>2016</year>
<volume>112</volume>
<fpage>6</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1016/j.bcp.2016.02.008</pub-id>
<pub-id pub-id-type="pmid">26898958</pub-id></element-citation>
</ref>
<ref id="B84-ijerph-13-01096">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pavek</surname><given-names>P.</given-names></name><name><surname>Cerveny</surname><given-names>L.</given-names></name><name><surname>Svecova</surname><given-names>L.</given-names></name><name><surname>Brysch</surname><given-names>M.</given-names></name><name><surname>Libra</surname><given-names>A.</given-names></name><name><surname>Vrzal</surname><given-names>R.</given-names></name><name><surname>Nachtigal</surname><given-names>P.</given-names></name><name><surname>Staud</surname><given-names>F.</given-names></name><name><surname>Ulrichova</surname><given-names>J.</given-names></name><name><surname>Fendrich</surname><given-names>Z.</given-names></name><etal></etal></person-group>
<article-title>Examination of Glucocorticoid receptor alpha-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines</article-title>
<source/>Placenta
<year>2007</year>
<volume>28</volume>
<fpage>1004</fpage>
<lpage>1011</lpage>
<pub-id pub-id-type="doi">10.1016/j.placenta.2007.05.001</pub-id>
<pub-id pub-id-type="pmid">17572486</pub-id></element-citation>
</ref>
<ref id="B85-ijerph-13-01096">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vreugdenhil</surname><given-names>E.</given-names></name><name><surname>Verissimo</surname><given-names>C.S.</given-names></name><name><surname>Mariman</surname><given-names>R.</given-names></name><name><surname>Kamphorst</surname><given-names>J.T.</given-names></name><name><surname>Barbosa</surname><given-names>J.S.</given-names></name><name><surname>Zweers</surname><given-names>T.</given-names></name><name><surname>Champagne</surname><given-names>D.L.</given-names></name><name><surname>Schouten</surname><given-names>T.</given-names></name><name><surname>Meijer</surname><given-names>O.C.</given-names></name><name><surname>de Kloet</surname><given-names>E.R.</given-names></name><etal></etal></person-group>
<article-title>MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: Implications for glucocorticoid responsiveness in the brain</article-title>
<source/>Endocrinology
<year>2009</year>
<volume>150</volume>
<fpage>2220</fpage>
<lpage>2228</lpage>
<pub-id pub-id-type="doi">10.1210/en.2008-1335</pub-id>
<pub-id pub-id-type="pmid">19131573</pub-id></element-citation>
</ref>
<ref id="B86-ijerph-13-01096">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Adams</surname><given-names>B.D.</given-names></name><name><surname>Furneaux</surname><given-names>H.</given-names></name><name><surname>White</surname><given-names>B.A.</given-names></name></person-group>
<article-title>The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines</article-title>
<source/>Mol. Endocrinol.
<year>2007</year>
<volume>21</volume>
<fpage>1132</fpage>
<lpage>1147</lpage>
<pub-id pub-id-type="doi">10.1210/me.2007-0022</pub-id>
<pub-id pub-id-type="pmid">17312270</pub-id></element-citation>
</ref>
<ref id="B87-ijerph-13-01096">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J.J.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Kong</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>L.</given-names></name><name><surname>Ma</surname><given-names>X.</given-names></name><name><surname>Coppola</surname><given-names>D.</given-names></name><name><surname>Cheng</surname><given-names>J.Q.</given-names></name></person-group>
<article-title>MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer</article-title>
<source/>J. Biol. Chem.
<year>2008</year>
<volume>283</volume>
<fpage>31079</fpage>
<lpage>31086</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M806041200</pub-id>
<pub-id pub-id-type="pmid">18790736</pub-id></element-citation>
</ref>
<ref id="B88-ijerph-13-01096">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pandey</surname><given-names>D.P.</given-names></name><name><surname>Picard</surname><given-names>D.</given-names></name></person-group>
<article-title>MiR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA</article-title>
<source/>Mol. Cell. Biol.
<year>2009</year>
<volume>29</volume>
<fpage>3783</fpage>
<lpage>3790</lpage>
<pub-id pub-id-type="doi">10.1128/MCB.01875-08</pub-id>
<pub-id pub-id-type="pmid">19414598</pub-id></element-citation>
</ref>
<ref id="B89-ijerph-13-01096">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xiong</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>D.</given-names></name><name><surname>Wei</surname><given-names>N.</given-names></name><name><surname>Fu</surname><given-names>H.</given-names></name><name><surname>Cai</surname><given-names>T.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Du</surname><given-names>Q.</given-names></name><name><surname>Lin</surname><given-names>D.</given-names></name><etal></etal></person-group>
<article-title>An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples</article-title>
<source/>FEBS J.
<year>2010</year>
<volume>277</volume>
<fpage>1684</fpage>
<lpage>1694</lpage>
<pub-id pub-id-type="doi">10.1111/j.1742-4658.2010.07594.x</pub-id>
<pub-id pub-id-type="pmid">20180843</pub-id></element-citation>
</ref>
<ref id="B90-ijerph-13-01096">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tang</surname><given-names>L.</given-names></name><name><surname>Pu</surname><given-names>Y.</given-names></name><name><surname>Wong</surname><given-names>D.K.</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Xiang</surname><given-names>T.</given-names></name><name><surname>Yuen</surname><given-names>M.F.</given-names></name><name><surname>Ren</surname><given-names>G.</given-names></name></person-group>
<article-title>The hepatitis B virus-associated estrogen receptor alpha (ERalpha) was regulated by microRNA-130a in HepG2.2.15 human hepatocellular carcinoma cells</article-title>
<source/>Acta Biochim. Biophys. Sin.
<year>2011</year>
<volume>43</volume>
<fpage>640</fpage>
<lpage>646</lpage>
<pub-id pub-id-type="doi">10.1093/abbs/gmr051</pub-id>
<pub-id pub-id-type="pmid">21712254</pub-id></element-citation>
</ref>
<ref id="B91-ijerph-13-01096">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Lv</surname><given-names>G.C.</given-names></name><name><surname>Sheng</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>Y.D.</given-names></name></person-group>
<article-title>Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD</article-title>
<source/>J. Gastroenterol. Hepatol.
<year>2010</year>
<volume>25</volume>
<fpage>156</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="doi">10.1111/j.1440-1746.2009.05949.x</pub-id>
<pub-id pub-id-type="pmid">19780876</pub-id></element-citation>
</ref>
<ref id="B92-ijerph-13-01096">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kida</surname><given-names>K.</given-names></name><name><surname>Nakajima</surname><given-names>M.</given-names></name><name><surname>Mohri</surname><given-names>T.</given-names></name><name><surname>Oda</surname><given-names>Y.</given-names></name><name><surname>Takagi</surname><given-names>S.</given-names></name><name><surname>Fukami</surname><given-names>T.</given-names></name><name><surname>Yokoi</surname><given-names>T.</given-names></name></person-group>
<article-title>PPARalpha is regulated by miR-21 and miR-27b in human liver</article-title>
<source/>Pharm. Res.
<year>2011</year>
<volume>28</volume>
<fpage>2467</fpage>
<lpage>2476</lpage>
<pub-id pub-id-type="doi">10.1007/s11095-011-0473-y</pub-id>
<pub-id pub-id-type="pmid">21562928</pub-id></element-citation>
</ref>
<ref id="B93-ijerph-13-01096">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tong</surname><given-names>J.L.</given-names></name><name><surname>Zhang</surname><given-names>C.P.</given-names></name><name><surname>Nie</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>X.T.</given-names></name><name><surname>Zhu</surname><given-names>M.M.</given-names></name><name><surname>Xiao</surname><given-names>S.D.</given-names></name><name><surname>Ran</surname><given-names>Z.H.</given-names></name></person-group>
<article-title>MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells</article-title>
<source/>FEBS Lett.
<year>2011</year>
<volume>585</volume>
<fpage>3560</fpage>
<lpage>3568</lpage>
<pub-id pub-id-type="doi">10.1016/j.febslet.2011.10.021</pub-id>
<pub-id pub-id-type="pmid">22036718</pub-id></element-citation>
</ref>
<ref id="B94-ijerph-13-01096">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ou</surname><given-names>Z.</given-names></name><name><surname>Wada</surname><given-names>T.</given-names></name><name><surname>Gramignoli</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Strom</surname><given-names>S.C.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Xie</surname><given-names>W.</given-names></name></person-group>
<article-title>MicroRNA hsa-miR-613 targets the human LXRalpha gene and mediates a feedback loop of LXRalpha autoregulation</article-title>
<source/>Mol. Endocrinol.
<year>2011</year>
<volume>25</volume>
<fpage>584</fpage>
<lpage>596</lpage>
<pub-id pub-id-type="doi">10.1210/me.2010-0360</pub-id>
<pub-id pub-id-type="pmid">21310851</pub-id></element-citation>
</ref>
<ref id="B95-ijerph-13-01096">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhong</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Zeng</surname><given-names>Y.J.</given-names></name><name><surname>Gao</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>G.Z.</given-names></name><name><surname>Hu</surname><given-names>C.J.</given-names></name><name><surname>Huang</surname><given-names>G.</given-names></name><name><surname>He</surname><given-names>F.T.</given-names></name></person-group>
<article-title>MicroRNA-613 represses lipogenesis in HepG2 cells by downregulating LXRalpha</article-title>
<source/>Lipids Health Dis.
<year>2013</year>
<volume>12</volume>
<fpage>32</fpage>
<pub-id pub-id-type="doi">10.1186/1476-511X-12-32</pub-id>
<pub-id pub-id-type="pmid">23496987</pub-id></element-citation>
</ref>
<ref id="B96-ijerph-13-01096">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vinod</surname><given-names>M.</given-names></name><name><surname>Chennamsetty</surname><given-names>I.</given-names></name><name><surname>Colin</surname><given-names>S.</given-names></name><name><surname>Belloy</surname><given-names>L.</given-names></name><name><surname>De Paoli</surname><given-names>F.</given-names></name><name><surname>Schaider</surname><given-names>H.</given-names></name><name><surname>Graier</surname><given-names>W.F.</given-names></name><name><surname>Frank</surname><given-names>S.</given-names></name><name><surname>Kratky</surname><given-names>D.</given-names></name><name><surname>Staels</surname><given-names>B.</given-names></name><etal></etal></person-group>
<article-title>MiR-206 controls LXRalpha expression and promotes LXR-mediated cholesterol efflux in macrophages</article-title>
<source/>Biochim. Biophys. Acta
<year>2014</year>
<volume>1841</volume>
<fpage>827</fpage>
<lpage>835</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbalip.2014.02.006</pub-id>
<pub-id pub-id-type="pmid">24603323</pub-id></element-citation>
</ref>
<ref id="B97-ijerph-13-01096">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu</surname><given-names>A.M.</given-names></name></person-group>
<article-title>Role of microRNAs in the regulation of drug metabolism and disposition</article-title>
<source/>Expert Opin. Drug Metab. Toxicol.
<year>2009</year>
<volume>5</volume>
<fpage>1513</fpage>
<lpage>1528</lpage>
<pub-id pub-id-type="doi">10.1517/17425250903307448</pub-id>
<pub-id pub-id-type="pmid">19785514</pub-id></element-citation>
</ref>
<ref id="B98-ijerph-13-01096">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>A.C.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Radecki</surname><given-names>L.</given-names></name><name><surname>Pan</surname><given-names>Y.Z.</given-names></name><name><surname>Winter</surname><given-names>J.C.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Yu</surname><given-names>A.M.</given-names></name></person-group>
<article-title>MicroRNA expression is differentially altered by xenobiotic drugs in different human cell lines</article-title>
<source/>Biopharm. Drug Dispos.
<year>2011</year>
<volume>32</volume>
<fpage>355</fpage>
<lpage>367</lpage>
<pub-id pub-id-type="doi">10.1002/bdd.764</pub-id>
<pub-id pub-id-type="pmid">21796641</pub-id></element-citation>
</ref>
<ref id="B99-ijerph-13-01096">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pogribny</surname><given-names>I.P.</given-names></name><name><surname>Filkowski</surname><given-names>J.N.</given-names></name><name><surname>Tryndyak</surname><given-names>V.P.</given-names></name><name><surname>Golubov</surname><given-names>A.</given-names></name><name><surname>Shpyleva</surname><given-names>S.I.</given-names></name><name><surname>Kovalchuk</surname><given-names>O.</given-names></name></person-group>
<article-title>Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin</article-title>
<source/>Int. J. Cancer
<year>2010</year>
<volume>127</volume>
<fpage>1785</fpage>
<lpage>1794</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.25191</pub-id>
<pub-id pub-id-type="pmid">20099276</pub-id></element-citation>
</ref>
<ref id="B100-ijerph-13-01096">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>K.</given-names></name><name><surname>Tatsumi</surname><given-names>N.</given-names></name><name><surname>Fukami</surname><given-names>T.</given-names></name><name><surname>Yokoi</surname><given-names>T.</given-names></name><name><surname>Nakajima</surname><given-names>M.</given-names></name></person-group>
<article-title>Integrated analysis of rifampicin-induced microRNA and gene expression changes in human hepatocytes</article-title>
<source/>Drug Metab. Pharm.
<year>2014</year>
<volume>29</volume>
<fpage>333</fpage>
<lpage>340</lpage>
<pub-id pub-id-type="doi">10.2133/dmpk.DMPK-13-RG-114</pub-id>
</element-citation>
</ref>
<ref id="B101-ijerph-13-01096">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Benson</surname><given-names>E.A.</given-names></name><name><surname>Eadon</surname><given-names>M.T.</given-names></name><name><surname>Desta</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>H.</given-names></name><name><surname>Burgess</surname><given-names>K.S.</given-names></name><name><surname>Segar</surname><given-names>M.W.</given-names></name><name><surname>Gaedigk</surname><given-names>A.</given-names></name><name><surname>Skaar</surname><given-names>T.C.</given-names></name></person-group>
<article-title>Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes</article-title>
<source/>Front. Pharmacol.
<year>2016</year>
<pub-id pub-id-type="doi">10.3389/fphar.2016.00111</pub-id>
<pub-id pub-id-type="pmid">27199754</pub-id></element-citation>
</ref>
<ref id="B102-ijerph-13-01096">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Lu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Yue</surname><given-names>W.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name></person-group>
<article-title>MirSNP, a database of polymorphisms altering miRNA target sites, identifies miRNA-related SNPs in GWAS SNPs and eQTLs</article-title>
<source/>BMC Genom.
<year>2012</year>
<volume>13</volume>
<elocation-id>661</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2164-13-661</pub-id>
<pub-id pub-id-type="pmid">23173617</pub-id></element-citation>
</ref>
<ref id="B103-ijerph-13-01096">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dzikiewicz-Krawczyk</surname><given-names>A.</given-names></name></person-group>
<article-title>MicroRNA polymorphisms as markers of risk, prognosis and treatment response in hematological malignancies</article-title>
<source/>Crit. Rev. Oncol. Hematol.
<year>2015</year>
<volume>93</volume>
<fpage>1</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.critrevonc.2014.08.006</pub-id>
<pub-id pub-id-type="pmid">25217091</pub-id></element-citation>
</ref>
<ref id="B104-ijerph-13-01096">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R.</given-names></name><name><surname>Naishadham</surname><given-names>D.</given-names></name><name><surname>Jemal</surname><given-names>A.</given-names></name></person-group>
<article-title>Cancer statistics, 2012</article-title>
<source/>CA Cancer J. Clin.
<year>2012</year>
<volume>62</volume>
<fpage>10</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.3322/caac.20138</pub-id>
<pub-id pub-id-type="pmid">22237781</pub-id></element-citation>
</ref>
<ref id="B105-ijerph-13-01096">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ding</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name><name><surname>Peng</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Guo</surname><given-names>Z.</given-names></name></person-group>
<article-title>A polymorphism at the miR-502 binding site in the 3’ untranslated region of the SET8 gene is associated with the outcome of small-cell lung cancer</article-title>
<source/>Exp. Ther. Med.
<year>2012</year>
<volume>3</volume>
<fpage>689</fpage>
<lpage>692</lpage>
<pub-id pub-id-type="pmid">22969952</pub-id></element-citation>
</ref>
<ref id="B106-ijerph-13-01096">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Yin</surname><given-names>Z.</given-names></name><name><surname>Gao</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Yin</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>P.</given-names></name><name><surname>Shu</surname><given-names>Y.</given-names></name></person-group>
<article-title>Genetic variation in a microRNA-502 minding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population</article-title>
<source/>PLoS ONE
<year>2013</year>
<volume>8</volume>
<elocation-id>e77024</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0077024</pub-id>
<pub-id pub-id-type="pmid">24146953</pub-id></element-citation>
</ref>
<ref id="B107-ijerph-13-01096">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Yang</surname><given-names>R.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Deng</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Huang</surname><given-names>D.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Qiu</surname><given-names>F.</given-names></name><etal></etal></person-group>
<article-title>A microRNA-135a/b binding polymorphism in CD133 confers decreased risk and favorable prognosis of lung cancer in Chinese by reducing CD133 expression</article-title>
<source/>Carcinogenesis
<year>2013</year>
<volume>34</volume>
<fpage>2292</fpage>
<lpage>2299</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgt181</pub-id>
<pub-id pub-id-type="pmid">23715500</pub-id></element-citation>
</ref>
<ref id="B108-ijerph-13-01096">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Campayo</surname><given-names>M.</given-names></name><name><surname>Navarro</surname><given-names>A.</given-names></name><name><surname>Vinolas</surname><given-names>N.</given-names></name><name><surname>Tejero</surname><given-names>R.</given-names></name><name><surname>Munoz</surname><given-names>C.</given-names></name><name><surname>Diaz</surname><given-names>T.</given-names></name><name><surname>Marrades</surname><given-names>R.</given-names></name><name><surname>Cabanas</surname><given-names>M.L.</given-names></name><name><surname>Gimferrer</surname><given-names>J.M.</given-names></name><name><surname>Gascon</surname><given-names>P.</given-names></name><etal></etal></person-group>
<article-title>A dual role for KRT81: A miR-SNP associated with recurrence in non-small-cell lung cancer and a novel marker of squamous cell lung carcinoma</article-title>
<source/>PLoS ONE
<year>2011</year>
<volume>6</volume>
<elocation-id>e22509</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0022509</pub-id>
<pub-id pub-id-type="pmid">21799879</pub-id></element-citation>
</ref>
<ref id="B109-ijerph-13-01096">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pu</surname><given-names>X.</given-names></name><name><surname>Roth</surname><given-names>J.A.</given-names></name><name><surname>Hildebrandt</surname><given-names>M.A.</given-names></name><name><surname>Ye</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>H.</given-names></name><name><surname>Minna</surname><given-names>J.D.</given-names></name><name><surname>Lippman</surname><given-names>S.M.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name></person-group>
<article-title>MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients</article-title>
<source/>Cancer Res.
<year>2013</year>
<volume>73</volume>
<fpage>1867</fpage>
<lpage>1875</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-0873</pub-id>
<pub-id pub-id-type="pmid">23378343</pub-id></element-citation>
</ref>
<ref id="B110-ijerph-13-01096">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Zandi</surname><given-names>R.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Ye</surname><given-names>Y.Q.</given-names></name><name><surname>Pertsemlidis</surname><given-names>A.</given-names></name><name><surname>Wu</surname><given-names>X.F.</given-names></name><name><surname>Roth</surname><given-names>J.A.</given-names></name><name><surname>Ji</surname><given-names>L.</given-names></name></person-group>
<article-title>A SNP in the 3’-untranslated region of FZD4 linked to lung cancer survival modulates a miRNA-mediated FZD4 transcript binding, cleavage, expression, and Wnt-signaling in NSCLC cells</article-title>
<source/>Cancer Res.
<year>2015</year>
<volume>75</volume>
<fpage>196</fpage>
<pub-id pub-id-type="doi">10.1158/1538-7445.AM2015-196</pub-id>
</element-citation>
</ref>
<ref id="B111-ijerph-13-01096">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Graziano</surname><given-names>F.</given-names></name><name><surname>Canestrari</surname><given-names>E.</given-names></name><name><surname>Loupakis</surname><given-names>F.</given-names></name><name><surname>Ruzzo</surname><given-names>A.</given-names></name><name><surname>Galluccio</surname><given-names>N.</given-names></name><name><surname>Santini</surname><given-names>D.</given-names></name><name><surname>Rocchi</surname><given-names>M.</given-names></name><name><surname>Vincenzi</surname><given-names>B.</given-names></name><name><surname>Salvatore</surname><given-names>L.</given-names></name><name><surname>Cremolini</surname><given-names>C.</given-names></name><etal></etal></person-group>
<article-title>Genetic modulation of the Let-7 microRNA binding to KRAS 3’-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan</article-title>
<source/>Pharmacogenom. J.
<year>2010</year>
<volume>10</volume>
<fpage>458</fpage>
<lpage>464</lpage>
<pub-id pub-id-type="doi">10.1038/tpj.2010.9</pub-id>
<pub-id pub-id-type="pmid">20177422</pub-id></element-citation>
</ref>
<ref id="B112-ijerph-13-01096">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sebio</surname><given-names>A.</given-names></name><name><surname>Pare</surname><given-names>L.</given-names></name><name><surname>Paez</surname><given-names>D.</given-names></name><name><surname>Salazar</surname><given-names>J.</given-names></name><name><surname>Gonzalez</surname><given-names>A.</given-names></name><name><surname>Sala</surname><given-names>N.</given-names></name><name><surname>del Rio</surname><given-names>E.</given-names></name><name><surname>Martin-Richard</surname><given-names>M.</given-names></name><name><surname>Tobena</surname><given-names>M.</given-names></name><name><surname>Barnadas</surname><given-names>A.</given-names></name><etal></etal></person-group>
<article-title>The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3’-untranslated region: Its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients</article-title>
<source/>Pharmacogenet. Genom.
<year>2013</year>
<volume>23</volume>
<fpage>142</fpage>
<lpage>147</lpage>
<pub-id pub-id-type="doi">10.1097/FPC.0b013e32835d9b0b</pub-id>
<pub-id pub-id-type="pmid">23324806</pub-id></element-citation>
</ref>
<ref id="B113-ijerph-13-01096">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Winder</surname><given-names>T.</given-names></name><name><surname>Ning</surname><given-names>Y.</given-names></name><name><surname>Pohl</surname><given-names>A.</given-names></name><name><surname>Yang</surname><given-names>D.</given-names></name><name><surname>Kahn</surname><given-names>M.</given-names></name><name><surname>Lurje</surname><given-names>G.</given-names></name><name><surname>Labonte</surname><given-names>M.J.</given-names></name><name><surname>Wilson</surname><given-names>P.M.</given-names></name><name><surname>Gordon</surname><given-names>M.A.</given-names></name><etal></etal></person-group>
<article-title>A let-7 microRNA-binding site polymorphism in 3’-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy</article-title>
<source/>Ann. Oncol.
<year>2011</year>
<volume>22</volume>
<fpage>104</fpage>
<lpage>109</lpage>
<pub-id pub-id-type="doi">10.1093/annonc/mdq315</pub-id>
<pub-id pub-id-type="pmid">20603437</pub-id></element-citation>
</ref>
<ref id="B114-ijerph-13-01096">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kjersem</surname><given-names>J.B.</given-names></name><name><surname>Ikdahl</surname><given-names>T.</given-names></name><name><surname>Guren</surname><given-names>T.</given-names></name><name><surname>Skovlund</surname><given-names>E.</given-names></name><name><surname>Sorbye</surname><given-names>H.</given-names></name><name><surname>Hamfjord</surname><given-names>J.</given-names></name><name><surname>Pfeiffer</surname><given-names>P.</given-names></name><name><surname>Glimelius</surname><given-names>B.</given-names></name><name><surname>Kersten</surname><given-names>C.</given-names></name><name><surname>Solvang</surname><given-names>H.</given-names></name><etal></etal></person-group>
<article-title>Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/− cetuximab</article-title>
<source/>BMC Cancer
<year>2012</year>
<volume>12</volume>
<elocation-id>534</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2407-12-534</pub-id>
<pub-id pub-id-type="pmid">23167843</pub-id></element-citation>
</ref>
<ref id="B115-ijerph-13-01096">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wynendaele</surname><given-names>J.</given-names></name><name><surname>Bohnke</surname><given-names>A.</given-names></name><name><surname>Leucci</surname><given-names>E.</given-names></name><name><surname>Nielsen</surname><given-names>S.J.</given-names></name><name><surname>Lambertz</surname><given-names>I.</given-names></name><name><surname>Hammer</surname><given-names>S.</given-names></name><name><surname>Sbrzesny</surname><given-names>N.</given-names></name><name><surname>Kubitza</surname><given-names>D.</given-names></name><name><surname>Wolf</surname><given-names>A.</given-names></name><name><surname>Gradhand</surname><given-names>E.</given-names></name><etal></etal></person-group>
<article-title>An illegitimate microRNA target site within the 3’ UTR of MDM4 affects ovarian cancer progression and chemosensitivity</article-title>
<source/>Cancer Res.
<year>2010</year>
<volume>70</volume>
<fpage>9641</fpage>
<lpage>9649</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0527</pub-id>
<pub-id pub-id-type="pmid">21084273</pub-id></element-citation>
</ref>
<ref id="B116-ijerph-13-01096">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liang</surname><given-names>D.</given-names></name><name><surname>Meyer</surname><given-names>L.</given-names></name><name><surname>Chang</surname><given-names>D.W.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Pu</surname><given-names>X.</given-names></name><name><surname>Ye</surname><given-names>Y.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>K.</given-names></name></person-group>
<article-title>Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response</article-title>
<source/>Cancer Res.
<year>2010</year>
<volume>70</volume>
<fpage>9765</fpage>
<lpage>9776</lpage>
<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0130</pub-id>
<pub-id pub-id-type="pmid">21118967</pub-id></element-citation>
</ref>
<ref id="B117-ijerph-13-01096">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Shan</surname><given-names>B.</given-names></name></person-group>
<article-title>A polymorphism at the miR-502 binding site in the 3’-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome</article-title>
<source/>Int. J. Cancer
<year>2012</year>
<volume>131</volume>
<fpage>1318</fpage>
<lpage>1322</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.27352</pub-id>
<pub-id pub-id-type="pmid">22095217</pub-id></element-citation>
</ref>
<ref id="B118-ijerph-13-01096">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Navarro</surname><given-names>A.</given-names></name><name><surname>Munoz</surname><given-names>C.</given-names></name><name><surname>Gaya</surname><given-names>A.</given-names></name><name><surname>Diaz-Beya</surname><given-names>M.</given-names></name><name><surname>Gel</surname><given-names>B.</given-names></name><name><surname>Tejero</surname><given-names>R.</given-names></name><name><surname>Diaz</surname><given-names>T.</given-names></name><name><surname>Martinez</surname><given-names>A.</given-names></name><name><surname>Monzo</surname><given-names>M.</given-names></name></person-group>
<article-title>MiR-SNPs as markers of toxicity and clinical outcome in Hodgkin lymphoma patients</article-title>
<source/>PLoS ONE
<year>2013</year>
<volume>8</volume>
<elocation-id>e64716</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0064716</pub-id>
<pub-id pub-id-type="pmid">23705004</pub-id></element-citation>
</ref>
<ref id="B119-ijerph-13-01096">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Larrea</surname><given-names>C.F.</given-names></name><name><surname>Navarro</surname><given-names>A.</given-names></name><name><surname>Tejero</surname><given-names>R.</given-names></name><name><surname>Tovar</surname><given-names>N.</given-names></name><name><surname>Diaz</surname><given-names>T.</given-names></name><name><surname>Cibeira</surname><given-names>M.T.</given-names></name><name><surname>Rosinol</surname><given-names>L.</given-names></name><name><surname>Ferrer</surname><given-names>G.</given-names></name><name><surname>Rovira</surname><given-names>M.</given-names></name><name><surname>Rozman</surname><given-names>M.</given-names></name><etal></etal></person-group>
<article-title>Impact of MiRSNPs on survival and progression in patients with multiple myeloma undergoing autologous stem cell transplantation</article-title>
<source/>Clin. Cancer Res.
<year>2012</year>
<volume>18</volume>
<fpage>3697</fpage>
<lpage>3704</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-0191</pub-id>
<pub-id pub-id-type="pmid">22539802</pub-id></element-citation>
</ref>
<ref id="B120-ijerph-13-01096">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Ding</surname><given-names>X.</given-names></name><name><surname>Zhuo</surname><given-names>Y.</given-names></name><name><surname>Ren</surname><given-names>P.</given-names></name><name><surname>Zhou</surname><given-names>C.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name></person-group>
<article-title>A miR-200b/200c/429-binding site polymorphism in the 3’ untranslated region of the AP-2alpha gene is associated with cisplatin resistance</article-title>
<source/>PLoS ONE
<year>2011</year>
<volume>6</volume>
<elocation-id>e29043</elocation-id>
<pub-id pub-id-type="pmid">22194984</pub-id></element-citation>
</ref>
<ref id="B121-ijerph-13-01096">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bao</surname><given-names>B.Y.</given-names></name><name><surname>Pao</surname><given-names>J.B.</given-names></name><name><surname>Huang</surname><given-names>C.N.</given-names></name><name><surname>Pu</surname><given-names>Y.S.</given-names></name><name><surname>Chang</surname><given-names>T.Y.</given-names></name><name><surname>Lan</surname><given-names>Y.H.</given-names></name><name><surname>Lu</surname><given-names>T.L.</given-names></name><name><surname>Lee</surname><given-names>H.Z.</given-names></name><name><surname>Juang</surname><given-names>S.H.</given-names></name><name><surname>Chen</surname><given-names>L.M.</given-names></name><etal></etal></person-group>
<article-title>Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy</article-title>
<source/>Clin. Cancer Res.
<year>2011</year>
<volume>17</volume>
<fpage>928</fpage>
<lpage>936</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-2648</pub-id>
<pub-id pub-id-type="pmid">21149617</pub-id></element-citation>
</ref>
<ref id="B122-ijerph-13-01096">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>S.P.</given-names></name><name><surname>Levesque</surname><given-names>E.</given-names></name><name><surname>Guillemette</surname><given-names>C.</given-names></name><name><surname>Yu</surname><given-names>C.C.</given-names></name><name><surname>Huang</surname><given-names>C.Y.</given-names></name><name><surname>Lin</surname><given-names>V.C.</given-names></name><name><surname>Chung</surname><given-names>I.C.</given-names></name><name><surname>Chen</surname><given-names>L.C.</given-names></name><name><surname>Laverdiere</surname><given-names>I.</given-names></name><name><surname>Lacombe</surname><given-names>L.</given-names></name><etal></etal></person-group>
<article-title>Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer</article-title>
<source/>Int. J. Cancer
<year>2014</year>
<volume>135</volume>
<fpage>2661</fpage>
<lpage>2667</lpage>
<pub-id pub-id-type="doi">10.1002/ijc.28904</pub-id>
<pub-id pub-id-type="pmid">24740842</pub-id></element-citation>
</ref>
<ref id="B123-ijerph-13-01096">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhan</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>W.</given-names></name><name><surname>Han</surname><given-names>B.</given-names></name><name><surname>Gao</surname><given-names>G.</given-names></name><name><surname>Qiao</surname><given-names>R.</given-names></name><name><surname>Lv</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Fan</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><etal></etal></person-group>
<article-title>Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population</article-title>
<source/>J. Clin. Lab. Anal.
<year>2012</year>
<volume>26</volume>
<fpage>441</fpage>
<lpage>446</lpage>
<pub-id pub-id-type="doi">10.1002/jcla.21544</pub-id>
<pub-id pub-id-type="pmid">23143626</pub-id></element-citation>
</ref>
<ref id="B124-ijerph-13-01096">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hong</surname><given-names>M.J.</given-names></name><name><surname>Choi</surname><given-names>Y.Y.</given-names></name><name><surname>Jang</surname><given-names>J.A.</given-names></name><name><surname>Jung</surname><given-names>H.J.</given-names></name><name><surname>Lee</surname><given-names>S.Y.</given-names></name><name><surname>Lee</surname><given-names>W.K.</given-names></name><name><surname>Yoo</surname><given-names>S.S.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Cha</surname><given-names>S.I.</given-names></name><name><surname>Kim</surname><given-names>C.H.</given-names></name><etal></etal></person-group>
<article-title>Association between genetic variants in pre-microRNAs and survival of early-stage NSCLC</article-title>
<source/>J. Thorac. Oncol.
<year>2013</year>
<volume>8</volume>
<fpage>703</fpage>
<lpage>710</lpage>
<pub-id pub-id-type="doi">10.1097/JTO.0b013e318288dc0a</pub-id>
<pub-id pub-id-type="pmid">23470291</pub-id></element-citation>
</ref>
<ref id="B125-ijerph-13-01096">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Yin</surname><given-names>Z.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Gao</surname><given-names>W.</given-names></name><name><surname>Qian</surname><given-names>Y.</given-names></name><name><surname>Pei</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Shu</surname><given-names>Y.</given-names></name></person-group>
<article-title>A genetic polymorphism in pre-miR-27a confers clinical outcome of non-small cell lung cancer in a Chinese population</article-title>
<source/>PLoS ONE
<year>2013</year>
<volume>8</volume>
<elocation-id>e79135</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0079135</pub-id>
<pub-id pub-id-type="pmid">24223174</pub-id></element-citation>
</ref>
<ref id="B126-ijerph-13-01096">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Wei</surname><given-names>Q.</given-names></name><name><surname>Hu</surname><given-names>L.</given-names></name><name><surname>Chen</surname><given-names>F.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name><name><surname>Heist</surname><given-names>R.S.</given-names></name><name><surname>Su</surname><given-names>L.</given-names></name><name><surname>Amos</surname><given-names>C.I.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Christiani</surname><given-names>D.C.</given-names></name></person-group>
<article-title>Polymorphisms in MicroRNAs are associated with survival in non-small cell lung cancer</article-title>
<source/>Cancer Epidemiol. Biomarkers Prev.
<year>2014</year>
<volume>23</volume>
<fpage>2503</fpage>
<lpage>2511</lpage>
<pub-id pub-id-type="doi">10.1158/1055-9965.EPI-14-0389</pub-id>
<pub-id pub-id-type="pmid">25103824</pub-id></element-citation>
</ref>
<ref id="B127-ijerph-13-01096">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Guo</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Ding</surname><given-names>C.</given-names></name></person-group>
<article-title>A microRNA-related single nucleotide polymorphism of the XPO5 gene is associated with survival of small cell lung cancer patients</article-title>
<source/>Biomed. Rep.
<year>2013</year>
<volume>1</volume>
<fpage>545</fpage>
<lpage>548</lpage>
<pub-id pub-id-type="pmid">24648983</pub-id></element-citation>
</ref>
<ref id="B128-ijerph-13-01096">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boni</surname><given-names>V.</given-names></name><name><surname>Zarate</surname><given-names>R.</given-names></name><name><surname>Villa</surname><given-names>J.C.</given-names></name><name><surname>Bandres</surname><given-names>E.</given-names></name><name><surname>Gomez</surname><given-names>M.A.</given-names></name><name><surname>Maiello</surname><given-names>E.</given-names></name><name><surname>Garcia-Foncillas</surname><given-names>J.</given-names></name><name><surname>Aranda</surname><given-names>E.</given-names></name></person-group>
<article-title>Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan</article-title>
<source/>Pharmacogenom. J.
<year>2011</year>
<volume>11</volume>
<fpage>429</fpage>
<lpage>436</lpage>
<pub-id pub-id-type="doi">10.1038/tpj.2010.58</pub-id>
<pub-id pub-id-type="pmid">20585341</pub-id></element-citation>
</ref>
<ref id="B129-ijerph-13-01096">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>M.</given-names></name><name><surname>Gu</surname><given-names>J.</given-names></name><name><surname>Eng</surname><given-names>C.</given-names></name><name><surname>Ellis</surname><given-names>L.M.</given-names></name><name><surname>Hildebrandt</surname><given-names>M.A.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Calin</surname><given-names>G.A.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Dubois</surname><given-names>R.N.</given-names></name><etal></etal></person-group>
<article-title>Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients</article-title>
<source/>Clin. Cancer Res.
<year>2012</year>
<volume>18</volume>
<fpage>3982</fpage>
<lpage>3991</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-2951</pub-id>
<pub-id pub-id-type="pmid">22661538</pub-id></element-citation>
</ref>
<ref id="B130-ijerph-13-01096">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pardini</surname><given-names>B.</given-names></name><name><surname>Rosa</surname><given-names>F.</given-names></name><name><surname>Naccarati</surname><given-names>A.</given-names></name><name><surname>Vymetalkova</surname><given-names>V.</given-names></name><name><surname>Ye</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>di Gaetano</surname><given-names>C.</given-names></name><name><surname>Buchler</surname><given-names>T.</given-names></name><name><surname>Novotny</surname><given-names>J.</given-names></name><name><surname>Matullo</surname><given-names>G.</given-names></name><etal></etal></person-group>
<article-title>Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients</article-title>
<source/>Carcinogenesis
<year>2015</year>
<volume>36</volume>
<fpage>82</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgu224</pub-id>
<pub-id pub-id-type="pmid">25368035</pub-id></element-citation>
</ref>
<ref id="B131-ijerph-13-01096">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ke</surname><given-names>H.L.</given-names></name><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Ye</surname><given-names>Y.</given-names></name><name><surname>Hildebrandt</surname><given-names>M.A.</given-names></name><name><surname>Wu</surname><given-names>W.J.</given-names></name><name><surname>Wei</surname><given-names>H.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Chang</surname><given-names>D.W.</given-names></name><name><surname>Dinney</surname><given-names>C.P.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name></person-group>
<article-title>Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer</article-title>
<source/>Carcinogenesis
<year>2013</year>
<volume>34</volume>
<fpage>1006</fpage>
<lpage>1011</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgt006</pub-id>
<pub-id pub-id-type="pmid">23322153</pub-id></element-citation>
</ref>
<ref id="B132-ijerph-13-01096">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>An</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Bao</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>J.J.</given-names></name></person-group>
<article-title>Single nucleotide polymorphisms of microRNA processing machinery genes and outcome of hepatocellular carcinoma</article-title>
<source/>PLoS ONE
<year>2014</year>
<volume>9</volume>
<elocation-id>e92791</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0092791</pub-id>
<pub-id pub-id-type="pmid">24676133</pub-id></element-citation>
</ref>
<ref id="B133-ijerph-13-01096">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Henrichsen</surname><given-names>C.N.</given-names></name><name><surname>Chaignat</surname><given-names>E.</given-names></name><name><surname>Reymond</surname><given-names>A.</given-names></name></person-group>
<article-title>Copy number variants, diseases and gene expression</article-title>
<source/>Hum. Mol. Genet.
<year>2009</year>
<volume>18</volume>
<fpage>R1</fpage>
<lpage>R8</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/ddp011</pub-id>
<pub-id pub-id-type="pmid">19297395</pub-id></element-citation>
</ref>
<ref id="B134-ijerph-13-01096">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duan</surname><given-names>S.</given-names></name><name><surname>Mi</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Dolan</surname><given-names>M.E.</given-names></name></person-group>
<article-title>Comprehensive analysis of the impact of SNPs and CNVs on human microRNAs and their regulatory genes</article-title>
<source/>RNA Biol.
<year>2009</year>
<volume>6</volume>
<fpage>412</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.4161/rna.6.4.8830</pub-id>
<pub-id pub-id-type="pmid">19458495</pub-id></element-citation>
</ref>
<ref id="B135-ijerph-13-01096">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lian</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Tian</surname><given-names>H.</given-names></name><name><surname>Liang</surname><given-names>N.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>C.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>F.</given-names></name></person-group>
<article-title>Altered microRNA expression in patients with non-obstructive azoospermia</article-title>
<source/>Reprod. Biol. Endocrinol.
<year>2009</year>
<volume>7</volume>
<fpage>13</fpage>
<pub-id pub-id-type="doi">10.1186/1477-7827-7-13</pub-id>
<pub-id pub-id-type="pmid">19210773</pub-id></element-citation>
</ref>
<ref id="B136-ijerph-13-01096">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keller</surname><given-names>A.</given-names></name><name><surname>Leidinger</surname><given-names>P.</given-names></name><name><surname>Lange</surname><given-names>J.</given-names></name><name><surname>Borries</surname><given-names>A.</given-names></name><name><surname>Schroers</surname><given-names>H.</given-names></name><name><surname>Scheffler</surname><given-names>M.</given-names></name><name><surname>Lenhof</surname><given-names>H.P.</given-names></name><name><surname>Ruprecht</surname><given-names>K.</given-names></name><name><surname>Meese</surname><given-names>E.</given-names></name></person-group>
<article-title>Multiple sclerosis: microRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls</article-title>
<source/>PLoS ONE
<year>2009</year>
<volume>4</volume>
<elocation-id>e7440</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0007440</pub-id>
<pub-id pub-id-type="pmid">19823682</pub-id></element-citation>
</ref>
<ref id="B137-ijerph-13-01096">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marrale</surname><given-names>M.</given-names></name><name><surname>Albanese</surname><given-names>N.N.</given-names></name><name><surname>Cali</surname><given-names>F.</given-names></name><name><surname>Romano</surname><given-names>V.</given-names></name></person-group>
<article-title>Assessing the impact of copy number variants on miRNA genes in autism by Monte Carlo simulation</article-title>
<source/>PLoS ONE
<year>2014</year>
<volume>9</volume>
<elocation-id>e90947</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0090947</pub-id>
<pub-id pub-id-type="pmid">24667286</pub-id></element-citation>
</ref>
<ref id="B138-ijerph-13-01096">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Marcinkowska</surname><given-names>M.</given-names></name><name><surname>Szymanski</surname><given-names>M.</given-names></name><name><surname>Krzyzosiak</surname><given-names>W.J.</given-names></name><name><surname>Kozlowski</surname><given-names>P.</given-names></name></person-group>
<article-title>Copy number variation of microRNA genes in the human genome</article-title>
<source/>BMC Genom.
<year>2011</year>
<volume>12</volume>
<elocation-id>183</elocation-id>
<pub-id pub-id-type="doi">10.1186/1471-2164-12-183</pub-id>
<pub-id pub-id-type="pmid">21486463</pub-id></element-citation>
</ref>
<ref id="B139-ijerph-13-01096">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Han</surname><given-names>M.</given-names></name><name><surname>Zheng</surname><given-names>Y.</given-names></name></person-group>
<article-title>Comprehensive analysis of single nucleotide polymorphisms in human microRNAs</article-title>
<source/>PLoS ONE
<year>2013</year>
<volume>8</volume>
<elocation-id>e78028</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0078028</pub-id>
<pub-id pub-id-type="pmid">24223755</pub-id></element-citation>
</ref>
<ref id="B140-ijerph-13-01096">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rawlings-Goss</surname><given-names>R.A.</given-names></name><name><surname>Campbell</surname><given-names>M.C.</given-names></name><name><surname>Tishkoff</surname><given-names>S.A.</given-names></name></person-group>
<article-title>Global population-specific variation in miRNA associated with cancer risk and clinical biomarkers</article-title>
<source/>BMC Med. Genom.
<year>2014</year>
<volume>7</volume>
<elocation-id>53</elocation-id>
<pub-id pub-id-type="doi">10.1186/1755-8794-7-53</pub-id>
<pub-id pub-id-type="pmid">25169894</pub-id></element-citation>
</ref>
<ref id="B141-ijerph-13-01096">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Clark</surname><given-names>A.G.</given-names></name></person-group>
<article-title>Impact of microRNA regulation on variation in human gene expression</article-title>
<source/>Genome Res.
<year>2012</year>
<volume>22</volume>
<fpage>1243</fpage>
<lpage>1254</lpage>
<pub-id pub-id-type="doi">10.1101/gr.132514.111</pub-id>
<pub-id pub-id-type="pmid">22456605</pub-id></element-citation>
</ref>
<ref id="B142-ijerph-13-01096">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huang</surname><given-names>R.S.</given-names></name><name><surname>Gamazon</surname><given-names>E.R.</given-names></name><name><surname>Ziliak</surname><given-names>D.</given-names></name><name><surname>Wen</surname><given-names>Y.</given-names></name><name><surname>Im</surname><given-names>H.K.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Wing</surname><given-names>C.</given-names></name><name><surname>Duan</surname><given-names>S.</given-names></name><name><surname>Bleibel</surname><given-names>W.K.</given-names></name><name><surname>Cox</surname><given-names>N.J.</given-names></name><etal></etal></person-group>
<article-title>Population differences in microRNA expression and biological implications</article-title>
<source/>RNA Boil.
<year>2011</year>
<volume>8</volume>
<fpage>692</fpage>
<lpage>701</lpage>
<pub-id pub-id-type="doi">10.4161/rna.8.4.16029</pub-id>
<pub-id pub-id-type="pmid">21691150</pub-id></element-citation>
</ref>
<ref id="B143-ijerph-13-01096">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bovell</surname><given-names>L.C.</given-names></name><name><surname>Shanmugam</surname><given-names>C.</given-names></name><name><surname>Putcha</surname><given-names>B.D.</given-names></name><name><surname>Katkoori</surname><given-names>V.R.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Bae</surname><given-names>S.</given-names></name><name><surname>Singh</surname><given-names>K.P.</given-names></name><name><surname>Grizzle</surname><given-names>W.E.</given-names></name><name><surname>Manne</surname><given-names>U.</given-names></name></person-group>
<article-title>The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer</article-title>
<source/>Clin. Cancer Res.
<year>2013</year>
<volume>19</volume>
<fpage>3955</fpage>
<lpage>3965</lpage>
<pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-3302</pub-id>
<pub-id pub-id-type="pmid">23719259</pub-id></element-citation>
</ref>
<ref id="B144-ijerph-13-01096">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Yin</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Sun</surname><given-names>K.</given-names></name></person-group>
<article-title>Ethnic differences in microRNA-375 expression level and DNA methylation status in type 2 diabetes of Han and Kazak populations</article-title>
<source/>J. Diabetes Res.
<year>2014</year>
<volume>2014</volume>
<fpage>761938</fpage>
<pub-id pub-id-type="doi">10.1155/2014/761938</pub-id>
<pub-id pub-id-type="pmid">24741571</pub-id></element-citation>
</ref>
<ref id="B145-ijerph-13-01096">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Sundquist</surname><given-names>J.</given-names></name><name><surname>Zoller</surname><given-names>B.</given-names></name><name><surname>Memon</surname><given-names>A.A.</given-names></name><name><surname>Palmer</surname><given-names>K.</given-names></name><name><surname>Sundquist</surname><given-names>K.</given-names></name><name><surname>Bennet</surname><given-names>L.</given-names></name></person-group>
<article-title>Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2</article-title>
<source/>PLoS ONE
<year>2014</year>
<volume>9</volume>
<elocation-id>e86792</elocation-id>
<pub-id pub-id-type="doi">10.1371/journal.pone.0086792</pub-id>
<pub-id pub-id-type="pmid">24497980</pub-id></element-citation>
</ref>
<ref id="B146-ijerph-13-01096">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>E.</given-names></name><name><surname>Ji</surname><given-names>P.</given-names></name><name><surname>Ouyang</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>X.Y.</given-names></name><name><surname>Rubin</surname><given-names>D.C.</given-names></name><name><surname>Davidson</surname><given-names>N.O.</given-names></name><name><surname>Bergamaschi</surname><given-names>R.</given-names></name><name><surname>Shroyer</surname><given-names>K.R.</given-names></name><name><surname>Burke</surname><given-names>S.</given-names></name><etal></etal></person-group>
<article-title>Differential expression of miRNAs in colon cancer between African and Caucasian Americans: Implications for cancer racial health disparities</article-title>
<source/>Int. J. Oncol.
<year>2014</year>
<volume>45</volume>
<fpage>587</fpage>
<lpage>594</lpage>
<pub-id pub-id-type="doi">10.3892/ijo.2014.2469</pub-id>
<pub-id pub-id-type="pmid">24865442</pub-id></element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="ijerph-13-01096-f001" position="float">
<label>Figure 1</label>
<caption>
<p>MiRNA biogenesis and posttranslational silencing mechanism. The miRNA maturation includes the production of the primary miRNA transcript (pri-miRNA) by RNA polymerase II or III and cleavage of the pri-miRNA by Drosha in the nucleus. Pre-miRNAs are transported to the cytoplasm by Exportin 5 and are processed into miRNA/miRNA* duplexes by Dicer. Only one strand of the miRNA/miRNA* duplex is processed into the RNA-induced silencing complex (RISC), which subsequently acts on its target mRNAs through mRNA cleavage, translational repression or deadenylation, depending on the level of complementarity between the miRNA and its targets. ORF, open reading frame.</p>
</caption>
<graphic xlink:href="ijerph-13-01096-g001"></graphic>
</fig>
<fig id="ijerph-13-01096-f002" position="float">
<label>Figure 2</label>
<caption>
<p>Interplay between miRNA-mediated posttranscriptional regulation of drug disposition related genes expression and drug response. DMET: drug-metabolizing enzymes and transporters; TF: transcription factors; NR: nuclear receptors.</p>
</caption>
<graphic xlink:href="ijerph-13-01096-g002"></graphic>
</fig>
<table-wrap id="ijerph-13-01096-t001" position="float">
<object-id pub-id-type="pii">ijerph-13-01096-t001_Table 1</object-id>
<label>Table 1</label>
<caption>
<p>MiRNAs reported to regulate drug metabolism related genes.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Function</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Involved miRNA</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Identification Methods</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">DMEs</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CYP1A1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-18b, -20b</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Correlation, mRNA expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B9-ijerph-13-01096">9</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-892a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B11-ijerph-13-01096">11</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CYP2A3</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-126* <sup>a</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">mRNA/protein expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B13-ijerph-13-01096">13</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CYP1B1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-27b</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Correlation, Reporter assays, protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B14-ijerph-13-01096">14</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CYP2C8</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-103, -107</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, correlation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B17-ijerph-13-01096">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CYP2C9</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-128-3p</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EMSA, reporter assay, mRNA/protein expression, correlation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B18-ijerph-13-01096">18</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CYP2C19</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-103, -107</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Protein expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B17-ijerph-13-01096">17</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-29a-3p</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EMSA, mRNA/protein expression, correlation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B19-ijerph-13-01096">19</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CYP2E1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-378</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, correlation, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B20-ijerph-13-01096">20</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-132, -212 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B21-ijerph-13-01096">21</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CYP2J2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">let-7b</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B22-ijerph-13-01096">22</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CYP3A4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-27b</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B23-ijerph-13-01096">23</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-1, -532-3p, -577, -627</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, protein expression, correlation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B24-ijerph-13-01096">24</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-27a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, correlation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B26-ijerph-13-01096">26</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CYP7A1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-122a, -422a <sup>a</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B27-ijerph-13-01096">27</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">CYP24A1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-125b</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B29-ijerph-13-01096">29</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Transporters</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ABCB1/MDR1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">let-7g</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">mRNA/protein expression, correlation, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B33-ijerph-13-01096">33</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-27a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">mRNA/protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B34-ijerph-13-01096">34</xref>,<xref ref-type="bibr" rid="B35-ijerph-13-01096">35</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-451 <sup>a</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">mRNA/protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B34-ijerph-13-01096">34</xref>,<xref ref-type="bibr" rid="B36-ijerph-13-01096">36</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-298 <sup>a</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B37-ijerph-13-01096">37</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-223</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B38-ijerph-13-01096">38</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-508-5p</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B39-ijerph-13-01096">39</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-145</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B40-ijerph-13-01096">40</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ABCB9</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-31</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B41-ijerph-13-01096">41</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ABCC1/MRP1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-326</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B43-ijerph-13-01096">43</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-134</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">mRNA/protein expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B44-ijerph-13-01096">44</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-122</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">mRNA/protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B45-ijerph-13-01096">45</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-1291 <sup>a</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, and functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B46-ijerph-13-01096">46</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-7</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, correlation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B47-ijerph-13-01096">47</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ABCC2/MRP2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-379 </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B48-ijerph-13-01096">48</xref>,<xref ref-type="bibr" rid="B49-ijerph-13-01096">49</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-297 <sup>a</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B50-ijerph-13-01096">50</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">let-7c</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B51-ijerph-13-01096">51</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ABCC4/MRP4</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-125a/b</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA expression, correlation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B52-ijerph-13-01096">52</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-124a, -506 <sup>a</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, correlation, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B53-ijerph-13-01096">53</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ABCC5/MRP5</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-128</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, protein expression, functional assay</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B54-ijerph-13-01096">54</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ABCG2/BCRP</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-328</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B57-ijerph-13-01096">57</xref>,<xref ref-type="bibr" rid="B58-ijerph-13-01096">58</xref>,<xref ref-type="bibr" rid="B59-ijerph-13-01096">59</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-519c</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B60-ijerph-13-01096">60</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-212</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, protein expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B61-ijerph-13-01096">61</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-520h</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B62-ijerph-13-01096">62</xref>,<xref ref-type="bibr" rid="B63-ijerph-13-01096">63</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-181a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B64-ijerph-13-01096">64</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-487a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B65-ijerph-13-01096">65</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC6A4/SERT</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-16</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B66-ijerph-13-01096">66</xref>,<xref ref-type="bibr" rid="B67-ijerph-13-01096">67</xref>,<xref ref-type="bibr" rid="B68-ijerph-13-01096">68</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-15a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, protein expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B68-ijerph-13-01096">68</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A5/LAT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-126</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, correlation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B69-ijerph-13-01096">69</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC7A11</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-27a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B70-ijerph-13-01096">70</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC12A2</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-384 <sup>a</sup>, -494, -1246 <sup>a</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B71-ijerph-13-01096">71</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC15A1/PEPT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-92b</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, correlation, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B72-ijerph-13-01096">72</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">SLC16A1/MCT1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-124</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B73-ijerph-13-01096">73</xref>,<xref ref-type="bibr" rid="B74-ijerph-13-01096">74</xref>] </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Nuclear Receptor </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">HNF4α</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-24, -34a </td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B76-ijerph-13-01096">76</xref>,<xref ref-type="bibr" rid="B77-ijerph-13-01096">77</xref>] </td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-34a, -34c-5p, -449a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B78-ijerph-13-01096">78</xref>,<xref ref-type="bibr" rid="B79-ijerph-13-01096">79</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PXR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-148a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, protein expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B80-ijerph-13-01096">80</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">VDR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-27b</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B23-ijerph-13-01096">23</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-125b</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, EMSA, protein expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B30-ijerph-13-01096">30</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">GR</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-18, -124a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B85-ijerph-13-01096">85</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">ESR1</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-206</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B86-ijerph-13-01096">86</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-221, -222</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B87-ijerph-13-01096">87</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-22</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B88-ijerph-13-01096">88</xref>,<xref ref-type="bibr" rid="B89-ijerph-13-01096">89</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-130a</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B90-ijerph-13-01096">90</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">PPARα</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-10b, -21, -27b</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, correlation</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B91-ijerph-13-01096">91</xref>,<xref ref-type="bibr" rid="B92-ijerph-13-01096">92</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-506</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B93-ijerph-13-01096">93</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">LXRα</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-613 <sup>a</sup></td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">EMSA, reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B94-ijerph-13-01096">94</xref>,<xref ref-type="bibr" rid="B95-ijerph-13-01096">95</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">miR-206</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Reporter assay, mRNA/protein expression, functional assays</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B96-ijerph-13-01096">96</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p><sup>a</sup> MiRNAs that are not listed as bona fide miRNAs in MirGeneDB [<xref ref-type="bibr" rid="B5-ijerph-13-01096">5</xref>]. EMSA: electrophoresis mobility shift assay.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="ijerph-13-01096-t002" position="float">
<object-id pub-id-type="pii">ijerph-13-01096-t002_Table 2</object-id>
<label>Table 2</label>
<caption>
<p>MiRSNPs as biomarkers of chemotherapy response and survival.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Gene</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">MirSNPs</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Involved miRNAs</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Cancer Types</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">Association with Variant Allele</th>
<th align="center" colspan="1" rowspan="1" style="border-top:solid thin;border-bottom:solid thin" valign="middle">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">SET8</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs16917496 T &gt; C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-502</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SCLC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased OS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B105-ijerph-13-01096">105</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NSCLC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased OS and reduced risk of death</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B106-ijerph-13-01096">106</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">CD133</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs2240688 A &gt; C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-135a/b</td>
<td align="center" colspan="1" rowspan="1" valign="middle">LC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased OS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B107-ijerph-13-01096">107</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">KRT81</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs3660 C &gt; G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-17</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NSCLC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased time to recurrence</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B108-ijerph-13-01096">108</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">FAS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs2234978 A &gt; G </td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-651</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NSCLC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Reduced OS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B109-ijerph-13-01096">109</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">FZD4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs713065 A &gt; G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-204</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NSCLC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased OS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B109-ijerph-13-01096">109</xref>,<xref ref-type="bibr" rid="B110-ijerph-13-01096">110</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">KRAS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs61764370 T &gt; G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">let-7</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CRC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Poor response to cetuximab-irinotecan therapy and reduced OS/PFS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B111-ijerph-13-01096">111</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CRC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Resistance to anti-EGFR-based therapy</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B112-ijerph-13-01096">112</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CRC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Improved OS/PFS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B113-ijerph-13-01096">113</xref>,<xref ref-type="bibr" rid="B114-ijerph-13-01096">114</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">MDM4</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs4245739 C &gt; A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-191</td>
<td align="center" colspan="1" rowspan="1" valign="middle">OC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Delayed progression and tumor related death</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B115-ijerph-13-01096">115</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs10900596 G &gt; A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-409-3p <sup>a</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">OC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Better treatment response</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B116-ijerph-13-01096">116</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">PDGFC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs1425486 G &gt; A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-425</td>
<td align="center" colspan="1" rowspan="1" valign="middle">OC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Poor treatment response and reduced OS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B116-ijerph-13-01096">116</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">KRAS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs10771184 T &gt; A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-544</td>
<td align="center" colspan="1" rowspan="1" valign="middle">OC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Better treatment response and increased OS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B116-ijerph-13-01096">116</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">SET8 </td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs16917496 T &gt; C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-502</td>
<td align="center" colspan="1" rowspan="1" valign="middle">HCC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased OS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B117-ijerph-13-01096">117</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">KRT81</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs3660 C &gt; G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-17</td>
<td align="center" colspan="1" rowspan="1" valign="middle">HL</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased risk of neurological toxicity</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B118-ijerph-13-01096">118</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">KRT81</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs3660 C &gt; G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-17</td>
<td align="center" colspan="1" rowspan="1" valign="middle">MM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased OS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B119-ijerph-13-01096">119</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">AP-2α</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs1045385 A &gt; C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-200b, -200c, -429</td>
<td align="center" colspan="1" rowspan="1" valign="middle">BC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased cisplatin sensitivity</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B120-ijerph-13-01096">120</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">CDON</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs3737336 T &gt; C </td>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-181c, -5007 <sup>a</sup>
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">PC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Recreased PFS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B121-ijerph-13-01096">121</xref>,<xref ref-type="bibr" rid="B122-ijerph-13-01096">122</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-196a-2</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs11614913 C &gt; T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NSCLC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Decreased risk of overall toxicity and increased OS/DFS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B123-ijerph-13-01096">123</xref>,<xref ref-type="bibr" rid="B124-ijerph-13-01096">124</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-149</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs2292832 T &gt; C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NSCLC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased OS/DFS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B124-ijerph-13-01096">124</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">pre-miR-27a</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs895819 A &gt; G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NSCLC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Poor treatment response and reduced OS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B125-ijerph-13-01096">125</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-5197 <sup>a</sup></td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs2042253 T &gt; C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NSCLC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased OS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B126-ijerph-13-01096">126</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">DROSHA</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs6886834 G &gt; A</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NSCLC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Reduced RFS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B109-ijerph-13-01096">109</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">XPO5</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs11077 A &gt; C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">NSCLC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased time to recurrence</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B108-ijerph-13-01096">108</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">SCLC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Reduced OS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B127-ijerph-13-01096">127</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">pri-miR-26a-1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs7372209 C &gt; T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CRC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Reduced time to progression</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B128-ijerph-13-01096">128</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">pri-miR-100</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs1834306 T &gt; C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CRC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased time to progression</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B128-ijerph-13-01096">128</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-219-1</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs213210 T &gt; C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CRC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased RFS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B129-ijerph-13-01096">129</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CRC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased OS/RFS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B130-ijerph-13-01096">130</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">miR-608</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs4919510 C &gt; G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CRC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Decreased RFS </td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B129-ijerph-13-01096">129</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">CRC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased EFS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B130-ijerph-13-01096">130</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">KIF3C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs6728684 T &gt; G</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">PC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Reduced PFS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B124-ijerph-13-01096">124</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">IFI30</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs1045747 T &gt; C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">PC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Reduced PFS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B121-ijerph-13-01096">121</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">DDX20</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs197412 C &gt; T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">BC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Decreased risk of recurrence</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B131-ijerph-13-01096">131</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">DGCR8</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs2073778 G &gt; T</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">BC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased risk of progression</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B131-ijerph-13-01096">131</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">XPO5</td>
<td align="center" colspan="1" rowspan="1" valign="middle">rs11077 A &gt; C</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">MM</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased OS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B119-ijerph-13-01096">119</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">HL</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased OS/DFS for heterozygotes</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B118-ijerph-13-01096">118</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" valign="middle">HCC</td>
<td align="center" colspan="1" rowspan="1" valign="middle">Increased OS</td>
<td align="center" colspan="1" rowspan="1" valign="middle">[<xref ref-type="bibr" rid="B132-ijerph-13-01096">132</xref>]</td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">RNASEN</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">rs17408716 A &gt; G</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">
</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">OC</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">Better treatment response and increased OS</td>
<td align="center" colspan="1" rowspan="1" style="border-bottom:solid thin" valign="middle">[<xref ref-type="bibr" rid="B116-ijerph-13-01096">116</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p><sup>a</sup> MiRNAs that are not listed as bona fide miRNAs in MirGeneDB [<xref ref-type="bibr" rid="B5-ijerph-13-01096">5</xref>]. NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; LC: lung cancer; CRC: colorectal cancer; OC: Ovarian cancer; HCC: hepatocellular carcinoma; HL: Hodgkin lymphoma; MM: multiple myeloma; BC: bladder cancer; PC: prostate cancer.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>